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Abstract 
 
Over the past decade, studies in our laboratory have established that i) compared to 
systemic route of delivery, mucosal delivery of recombinant fowlpox virus (rFPV) 
prime can induce excellent high avidity mucosal/systemic HIV-specific CD8+ T cell 
immunity, ii) this was associated with IL-4/IL-13 cytokine milieu and iii) transient 
inhibition of IL-13 at the vaccination site can recruit unique lung dendritic cell (DC) 
subsets, responsible for the induction of high quality CD8+ T cell immunity. Therefore, 
to understand which cells at the vaccination site was the predominant source of IL-13 
was assessed by evaluating the different cells at the vaccination site, specifically innate 
lymphoid cells (ILC) following rFPV vaccination with and without transient inhibition 
of IL-13. These studies for the first time revealed that ILC2 were the main source of IL-
13 at the vaccination site (24 h post vaccination) responsible for inducing high quality T 
and B cells immune responses reported previously. Intranasal vaccination induced 
ST2/IL-33R+ ILC2 in lung, whilst intramuscular vaccination exclusively induced IL-
25R+ ILC2 in muscle. Moreover, adjuvants that transiently inhibited IL-13 at the 
vaccination site significantly influenced the IFN-γ expression by ILC1/ILC3 indicating 
that ILC2-derived IL-13 at the vaccination site also modulated ILC1/ILC3 
function/activity. 
 
As intranasal and intramuscular vaccinations induced different ILC2 subsets, two rFPV 
vaccines co-expressing adjuvants that transiently sequestered IL-25 and IL-33 at the 
vaccination site (rFPV-IL-12BP and rFPV-IL-33BP) were used to further evaluate ILC 
development following vaccination. Unlike IL-13 inhibitor vaccination conditions, 
intranasal delivery of IL-25BP adjuvanted vaccine induced not only ST2/IL-33R+ ILC2 
but also IL-25R+ and TSLPR+ ILC2 subsets that were able to express IL-13. Moreover 
x 
 
TSLPR+ ILC2 subset was also able to express IL-4. Interestingly, intranasal delivery of 
IL-25BP also induced significantly elevated number of NKp46+/- ILC1/ILC3 expressing 
IL-17A compared to IFN-γ, unlike the unadjuvanted or IL-13 inhibitor conditions. 
Taken together, these inhibitor studies indicated that IL-25 play a fundamental role in 
early ILC development than IL-33, suggesting that there is a hierarchical regulation of 
ILC development, where IL-25 is most likely the master regulator of ILC. 
 
Data also revealed that ILC and their cytokine expression profiles were vastly different 
during permanent verses transient blockage of IL-13, and STAT6 at the vaccination site. 
STAT6-/- mice given the FPV-HIV vaccine showed elevated ST2/IL-33R+ ILC2-driven 
IL-13 expression whilst reduced IFN-γ expression by both NKp46+/- ILC1/ILC3, unlike 
transient blockage of STAT6 which showed the opposing effect. When IL-13-/- mice 
were vaccinated with FPV-HIV significantly elevated lung lineage- ST2/IL-33R+ ILC2s 
were detected compared to BALB/c mice given the FPV-HIV-IL-13Rα2 adjuvanted 
vaccine (transient inhibition of IL-13), and their NKp46+/- ILC1/ILC3-driven IFN-γ 
expression was significantly lower compared to transient inhibition of STAT6. In 
previous studies when IL-13 was inhibited, no or low antibody differentiation has been 
reported, unlike STAT6 inhibition. Thus, current data further corroborated that ST2/IL-
33R+ ILC2-derived IL-13 play a crucial role in modulating downstream B cell immune 
outcomes. Specifically, co-regulation of ST2/IL-33R+ ILC2-derived IL-13 and NKp46+/- 
ILC1/ILC3-derived IFN-γ may play an important role in modulating antibody 
differentiation process in a STAT6 independent manner via the IL-13Rα2 pathway.  
 
When trying to understand the molecular mechanism involved in this process, data 
revealed that the expression of IL-13Rα2, type I and II IL-4Rs on ST2/IL-33R+ ILC2 
and NKp46- ILC1/ILC3 were co-regulated 24 h post intranasal rFPV vaccination. 
xi 
 
Inhibition of STAT6 signalling significantly impacted the IL-13Rα2 expression on both 
ST2/IL-33R+ ILC2 and NKp46- ILC1/ILC3, unlike IL-13 inhibition, suggesting that 
under STAT6 inhibition conditions, IL-13 could signal via IL-13Rα2 pathway. As 
elevated number of ST2/IL-33R+ ILC2 expressing IL-13Rα2 were detected in BALB/c 
mice given the FPV-HIV-IL-4R antagonist vaccine, this also indicated an autocrine 
regulation of IL-13 at the ILC2 via IL-13Rα2. The Il-4/IL-13 receptor expression 
profile on NKp46+ ILC1/ILC3 and NKp46- ILC1/ILC3 were vastly different, suggesting 
that these cells may play different roles in downstream immune outcomes.  
 
Collectively, findings in this thesis demonstrated that i) ILC activity is significantly 
modulated by route of vaccine delivery and vaccine adjuvants early as 24 h post 
vaccination, ii) When designing vaccines against chronic pathogens, understanding the 
fundamental roles of ILC at the vaccination site may help design better vaccines in the 
future, iii) IL-25 regulated initial development/differentiation of all ILCs and IL-33 
most likely only play a role in ILC2 homing to the lung mucosae, iv) Post viral vector 
vaccination ILC-derived IL-13 and IFN−γ balance was crucial for shaping the 
downstream immune outcomes, v) The IL-13 regulation at the ILC level occurred via an 
STAT6 independent pathway, most likely IL-13Rα2 (due to low IL-13 conditions). In 
conclusion, this work has provided unique insights into ILC function and activity during 
viral vector vaccination, that could be used to tailor vaccine vectors to induce effective 
immune outcomes against target pathogens (for example TB verses an HIV vaccine). 
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1.1 The immune system overview diary. 
Humans and animals are continually exposed to microbes and harmful substances that 
are inhaled, swallowed, or inhabit the skin and mucous membranes. Whether these 
microbes and substances threaten normal homeostasis depends on their pathogenicity 
and the host defence mechanisms, which forms the immune system. The immune 
system is divided into two compartments determined by the speed and specificity of the 
responses. The innate immune system induces responses that are rapid but non-specific 
whilst the adaptive immune system is slow and induce pathogen-specific responses1 
(Fig. 1.1). 
 
1.1.1 Innate immune system. 
The physical, chemical, and microbiological barriers are the crucial first line of defence 
against pathogen invasion2 (Fig 1.2). For example, the skin, gastrointestinal, respiratory, 
and urogenital tracts contain epithelial cells which are joined by tight junctions and 
form an effective seal against the external environment. The internal epithelia are also 
known as mucosal epithelia because of their ability to secrete mucus3, 4, comprised of 
antimicrobial peptides, fatty acids, enzymes (specifically, lysozymes), α-defensins and 
β-defensins. Moreover, healthy epithelial surfaces also contain a large number of non-
pathogenic bacteria, known as the microbiota5, 6. Microbiota also helps strengthen the 
barrier functions of the epithelia by producing antimicrobial substances, such as lactic 
acid. There are also cells in the innate immune compartment, which express different 
sensing receptors, such as macrophages that express Toll-Like Receptors (TLRs). TLRs 
can recognise pathogens by binding their Pathogen Associated Molecular Patterns 
(PAMPs)7 to initiate defence against microbial pathogens. Moreover, antiviral activity 
induced by type I interferons (IFN) also play a crucial role in the innate immune 
system8, 9,10. 
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The innate immune system is comprised of a large number of cellular and humoral 
elements (Table 1.1). Most of these elements in the innate system are present before the 
onset of an infection, however these protective mechanisms are not pathogen specific. 
Key cells that are involved in this process include mast cells, macrophages, natural 
killer cells (NK cells), dendritic cells, monocytes, granulocytes, and also the newly 
discovered cytokine producing lineage negative cells known as innate lymphoid cells 
(ILC)11, 12, 13, 14, 15 (Fig. 1.3). Macrophages are activated by a variety of stimuli such as 
LPS, peptidoglycans and cytokines. Once they are activated, macrophages exhibit 
greater phagocytic activity and present antigen to TH cells which makes macrophages an 
important connection between the innate immune system and the adaptive immune 
system. NK cells contain special proteins such as perforin and serine proteases known 
as granzymes that have the ability to destroy the pathogen. The NK cells play a 
significant role in defence against viruses and also produce two anti-viral cytokines 
IFN-γ and TNF-α. Dendritic cells are the major antigen presenting cells in the innate 
compartment. According to the immune compartment (skin, lung and digestive tract,) 
resident DC subsets can be vastly different, upon activation these DCs migrate to lymph 
nodes, and present antigens to T cells and initiate the adaptive immune cascade. The 
cytokines produced in the innate compartment by different immune cells play an 
important role at the first line of defense16 activating the DC and macrophages shaping 
the downstream adaptive immune outcomes (Fig 1.4).  
 
1.1.2 Adaptive immune system. 
The vast variability of antigenic structures and their ability to mutate to avoid host 
defence mechanisms have driven the evolution of the adaptive immune system17. Unlike 
the recognition receptors of the innate immune system, which are invariant, and 
germline encoded, the adaptive immune responses rely on receptors that are generated  
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by random somatic gene segment rearrangement18, 19, 20, 21, 22, 23. After initial pathogen 
encounter, cells expressing these receptors can persist in the host for life, providing 
immunologic memory and capacity for rapid response in the event of re-exposure24.  
 
Cells of the adaptive immune system include the effectors of cellular immune responses, 
the T lymphocytes, which mature in the thymus, and antibody-producing cells, the B 
lymphocytes, which arise in the bone marrow25, 26. These T and B lymphocytes use their 
antigen-specific receptors to drive targeted effector responses in two stages (Fig. 1.5). 
First, the antigen is presented to T or B cells by APC, and then T and B cells begin to 
prime, activate, and differentiate. This stage usually occurs in specialised environment 
of lymphoid tissues. Second, the effector response takes place, where activated T cells 
leave the lymphoid tissue and home to the site of infection, and similarly the activated B 
cells start to produce antibodies which can be found in blood and tissue fluids11, 24, 25, 26, 
27, 28.  
 
1.2 The mucosal immune system. 
The mucosal immune system is the first line of defence in humans and higher animals. 
It consists of a single-layer epithelium covered by mucus and antimicrobial secretes and 
fortified by both innate and adaptive components of host defence29 (Fig. 1.6). Mucosal 
epithelium acts as a physical, chemical and a protective barrier, sensing and eliminating 
harmful pathogens (Fig. 1.6). The mucus secreted by goblet cells, forms a dense 
protective layer covering of the entire mucosal epithelium30. The paneth cells are able to 
produce anti-microbial peptides or α-defensins, and epithelial cells produce β-defensins 
for host protection31, 32. A network known as the mucosa-associated lymphoid tissue 
(MALT), plays an important role in initiating mucosal adaptive immune outcomes33. 
According to the anatomical location, the MALT is divided into gut- 
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associated lymphoid tissue (GALT), nasopharynx-associated lymphoid tissue (NALT), 
bronchus-associated lymphoid tissue (BALT) and urogenital associate lymphoid tissue 
(Fig. 1.7). 
 
GALT, is comprised of several lymphoid nodules; Peyer’s patches, isolated lymphoid 
follicles, cryptopatches, and lymphoglandular complexes34. Peyer’s patches are 
extremely important for the initiation of immune responses in the gut, which contain 
large number of B cell zones and also small number of T cell zones34. The subepithelial 
dome areas of Peyer’s patches are rich in dendritic cells, T cells, and B cells. The 
isolated lymphoid follicles, located on the antimesenteric border of the small intestine 
are very similar to Peyer’s patches and contain B cell follicles and an overlying follicle-
associated epithelium containing microfold cells (M cells), and also scattered dendritic 
cells with few macrophages35, 36. The M cells are unique to the mucosal compartment, 
which have a folded luminal surface and do not secret digestive enzymes or mucus and 
lack microvilli unlike other mucosal epithelial cells (Fig. 1.8). M cells are directly 
exposed to micro-organisms and particles within the gut lumen and help antigen enter 
the Peyer’s patches (Fig. 1.8)37. 
 
The NALT is composed of paired lymphoid aggregates in the caudoventral portion of 
the left and right nasal passages at the entrance to the nasopharyngeal duct34. Compared 
to gut Peyer’s patches, there are fewer intraepithelial lymphocytes in NALT, and the 
relative T and B cell zones areas are roughly equal in the NALT, unlike in the GALT 
where number of T cell zones are lower than B cell zones34. Similar to GALT, the 
lymphoepithelium of NALT also contains M cells38. BALT and urogenital associated 
lymphoid tissue also contain M cells. These M cells are known to uptake and present  
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antigens to mucosal dendritic cells, which in turn present antigens to T cells and initiate 
T cell homing38.  
 
1.3 Current state of HIV vaccines. 
Since the first characterisation of Human Immunodeficiency Virus (HIV) and Acquired 
Immune Deficiency Syndrome (AIDS) in 198139, more than 25 million people have 
died of the disease40. Currently according to WHO there are 36.7 million people living 
with HIV and 1.2 million have died in 2016 (UNAIDS global report 2017). Although 
effective anti-retroviral therapy is currently available, to effectively combat HIV, a 
vaccine with high efficacy is urgently needed, which is the only cost-effective solution, 
specifically in the developing countries. It is now well established that HIV is a mucosal 
infection as the transmission mainly occurs via the genito-rectal mucosae41.  HIV infects 
CD4+ T cells, and the first CD4+ T cells depletion occurs in the gut41. Interestingly, 
despite HIV being a mucosal infection, not many mucosal vaccine strategies have been 
tested in the clinic. The main difficulties of HIV vaccine development have been 
associated to i) the diversity of HIV, the virus having different clades and makes it 
difficult to design a universal vaccine; ii) inability to induce effective neutralising 
antibodies; iii) viral latency, due to viral integration to the host genome; and iv) inability 
to design an effective vaccine that target both the mucosal and the systemic 
compartments 42, 43, 44, 45. 
 
Over the past three decades, all human HIV clinical vaccine trials have used systemic 
route of delivery, and all these vaccines have yielded poor outcomes in humans (Table 
1.2). Early clinical trials of HIV vaccines attempted to use recombinant subunits or 
synthetic peptide fragments to elicit neutralising antibodies against viral antigens, such 
as Env proteins gp120 and gp41. These vaccines although induced strong antibody  
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binding showed no neutralising ability, or CD8+ T cell immunity46, 47. Following the 
VAX 004 trial using a recombinant HIV envelope glycoprotein subunit (rgp120) and a 
second envelope in alum adjuvant also showed no differences in protective efficacy 
among 3598 vaccines and 1805 placebo recipients48, 49, 50. VAX 003 trial which used a 
similar approach also showed no protective efficacy51, 52. DNA and adenovirus vector-
based vaccines although successful in the animal models have yielded poor outcomes in 
humans53, 54. The Thai phase RV144 trial which used recombinant canarypox prime 
followed by several gp120 Env boosters, has been the only trial that has shown any 
protective efficacy in humans (31%)55. In this trail, the partial protection was mainly 
associated with Env-specific IgG antibodies not IgA, or CD8+ T cell responses56, 57. 
Thus, it is now established that a vaccine strategy that can induce both high quality 
mucosal/systemic T cells and B cell immunity may be needed to induce full protection 
against HIV.  
 
1.4 Mucosal HIV vaccines. 
It is now well established that to induce effective, long-lasting mucosal immunity, a 
vaccine needs to be delivered to the mucosae, for example: intranasal, oral, rectal or 
intravaginal routes of delivery58, 59 (Fig. 1.9a), and systemic vaccination is unable to 
induce effective sustained immunity at the mucosae60, 61. Studies have now clearly 
established that following vaccination the adaptive immune responses can be 
significantly manipulated by the route of delivery, vaccine adjuvants/vectors, and the 
cytokine milieu at the vaccination site61, 62, 63, 64. 
 
1.4.1 Vaccine vectors and routes of vaccine delivery. 
Even though recombinant DNA vaccine strategies have shown to induce good immune 
responses against HIV in animal models65, 66, 67, they have not been effective in clinical 
19 
 
trials, mainly due to their poor up-take. Specifically, mucosal delivery of DNA vaccines 
has not been effective in both animals and humans60, 65. These complexities lead to the 
development of a range of live recombinant viral vector-based vaccines to deliver 
vaccine antigens against many chronic pathogens (for example malaria, HIV and TB)68, 
69, 70, 71, 72. For example, in the context of HIV, the Thailand RV 144 trial which showed 
partial protective efficacy (31.2%) used recombinant canarypox vector-based vaccine 
prime followed by several recombinant gp120 subunit vaccine booster vaccines55. Also, 
in this trial, heterologous prime-boost vaccination was proven to be more effective than 
the use of recombinant HIV vaccine vector alone.  
 
It is now well established that the route of delivery can significantly modulate the 
adaptive immune outcomes59, 61, 62. Specifically, although nasal vaccination can induce 
immunity in the upper respiratory tract, gut and the genito-rectal mucosae; oral 
vaccination has shown to induce poor or no immunity in the genito-rectal mucosae. 
Similarly, rectal immunisation can induce immunity in the rectum and larger intestine, 
whilst vaginal vaccination only can induce immunity in the vagina45 (Fig. 1.9b). 
Interestingly, systemic vaccination (for example intramuscular deliver), has shown to 
induce effective systemic immunity with transient immunity in the mucosae59, 73, 74. 
Thus, given that most instances HIV initially encounters the host via the mucosae, when 
designing HIV vaccines, it is now established that a strategy that can induce strong 
sustained immunity in the mucosae, such as intranasal or intra rectal delivery would be 
of importance.  
 
Our laboratory has performed extensive studies over a decade to understand different 
immune outcomes following different routes of prime-boost vaccination (systemic vs  
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mucosal) and the different vector combinations (for example recombinant DNA (rDNA), 
recombinant fowlpox (rFPV), Modified Vaccinia Ankara (MVA) and recombinant  
vaccinia virus (rVV) in mouse and non-human primate models60, 74, 75. These studies 
have shown that i) rFPV is an excellent mucosal delivery vector compared to rDNA, 
rMVA or rVV60, 74; ii) Intramuscular (i.m.) rDNA/intranasal (i.n.) rFPV prime-boost 
vaccine strategy can induce elevated HIV-specific systemic as well as mucosal T cell 
responses and IgG1, IgG2a and mucosal IgG, SIgA responses in mouse and macaque 
models60, 65; iii) However, unlike rDNA prime-boost strategy, i.n. rFPV/i.m. rVV 
strategy can induce strong sustained HIV-specific CD8+ T cells with higher avidity and 
better protective efficacy60, 74, iv) When designing viral vector-based vaccines vector 
combination plays an important role, where rFPV prime/rVV booster or influenza 
booster induce high avidity T cells whilst rVV or influenza prime induce low avidity T 
cell immunity76 and v) The route of vaccine delivery plays a crucial role in modulating 
avidity and magnitude of T cell responses75 where systemic delivery (intramuscular) 
induce low avidity HIV-specific CD8 T cells whereas, mucosal delivery (intranasal) can 
induce high avidity HIV-specific CD8+ T cells and this was associated with the level of 
IL-4 and IL-13 expressed by CD8 T cells75,77. 
 
1.4.2 Cytokine cell milieu. 
Ranasinghe et al for the first time demonstrated that pure systemic route (intramuscular 
– i.m.) of vaccination can generate lower avidity of HIV-specific CD8+ T cells with 
higher levels of IL-4 and IL-13 production compared to pure mucosal (intranasal – i.n.) 
or mucosal/systemic routes (i.n./i.m.) of vaccination77. Using IL-4 gene knock-out (IL-
4-/-) and IL-13 gene knock-out mice (IL-13-/-), studies have shown that IL-4-/- and IL-13-
/- mice are able to generate CD8+ T cells with higher avidity compared to WT mice 
given the same vaccination (i.n. FPV-HIV/i.m. VV-HIV)77. Furthermore, these studies 
23 
 
showed that IL-4 and IL-13 can significantly dampen CD8α expression on anti-viral 
CD8+ T cells, and reduce poly-functionality of these T cells (ability to produce a range 
of anti-viral cytokines- which is a hallmark of protective immunity)78. Furthermore, 
these studies also established that following viral infection down regulation of IL-4 
receptors α (IL-4Rα) is associated with the induction of higher avidity CD8+ T cells79. 
These studies clearly demonstrated that route of vaccination and IL-4/IL-13 levels play 
a detrimental role in modulating the quality of CD8+ T cells. 
 
1.5 IL-4 and IL-13 signalling pathway. 
IL-4 and IL-13 are two cytokines at the centre of type-2 inflammation, and since their 
discovery have been linked to allergy, asthma and atopic diseases 80, 81. IL-4 and IL-13 
are secreted by CD4+ T cells82, 83, CD8+ T cells84, 85, 86, mast cells and basophils87, 88, 89. 
In the last decade, the newly identified innate immune cell type 2 (ILC2) has also 
shown to express IL-13 and also IL-4 under certain conditions90, 91.  
 
IL-4 and IL-13 signal via a complex receptor system92 (Fig. 1.10). The type I IL-4 
receptor complex consists of the IL-4 receptor α (IL-4Rα) and common gamma chain 
(γC). The type II IL-4 receptor complex contains IL-4Rα and IL-13 receptor α1 (IL-
13Rα1)93. IL-4 can signal via both type I and type II receptor complex by binding IL-
4Rα with very high affinity and then resulting in the recruitment of either γC or IL-
13Rα194, 95, followed by the initialization of Janus Kinase/Signal Transducer and 
Activator of Transcription 6 (JAK/STAT6) signalling96, 97, 98 (Fig. 1.10). It is also 
thought that under certain conditions IL-4 can also signal via the Insulin Receptor 
Substrate-1/2 (IRS-1/2) pathway97, 99, 100, 101, 102, followed by the activation of 
Phosphoinositide 3-kinase (PI3-K)103, 104, 105,  
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Protein kinase B (also known as AKT)106, 107, 108, 109 and NF-κB-driven gene 
transcription110, 111. IL-13Rα1 is not only a subunit of the type II IL-4 receptor complex, 
but also the ligand binding subunit for IL-13. IL-13  
binds IL-13Rα1 with low affinity leading to recruitment of the IL-4Rα subunit and the 
activation of JAK/STAT6 signalling pathway93.  
 
IL-13 can also bind to IL-13 receptor α2 (IL-13Rα2) with high affinity (pM 
conditions)112. The IL-13Rα2 is considered as a decoy receptor for IL-13 in mice (not in 
humans) due to the lack of cytoplasmic tail signalling motifs112. However, recent studies 
in our laboratory have shown that this may not be a decoy receptor even in mice113. In 
mice, IL-13Rα2 is found as a cell surface form and a soluble form114, 115 but only the 
cell surface form is found in human116. Studies have shown that IL-13Rα2 can bind to 
IL-4Rα and inhibit IL-4/IL-13 signalling via the IL-13Rα1/IL-4Rα type II complex and 
JAK/STAT6 pathway117, 118, 119, 120. Also, in cancer studies IL-13Rα2 
activation/signalling has been associated with TGF-β production in the absence of 
functional IL-4Rα121. 
 
1.6 IL-4R antagonist and IL-13Rα2 adjuvanted mucosal HIV vaccines. 
Knowing that low IL-4 and IL-13 can induce high avidity HIV-specific CD8+ T cells 
and this is vaccine route dependent75, 77, ,in order to manipulate IL-4/IL-13 levels at the 
vaccination site, two pox viral vector-based vaccines were designed in our laboratory, i) 
IL-4R antagonist vaccine and ii) IL-13Rα2 adjuvanted vaccine. Both these vaccines 
were able to transiently inhibit IL-4 and/or IL-13 activity at the vaccination site113, 122 
(Fig. 1.11). The IL-13Rα2 adjuvanted vaccine co-expressed HIV antigens together with 
soluble IL-13Rα2, which could sequester IL-13 at the vaccination site, when given to 
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wild type BALB/c mice were able to behave very similar to an IL-13 knockout 
animal122 (Fig. 1.11a). The IL-4R antagonist adjuvanted vaccine that co-expressed HIV 
antigens together with C-terminal deletion mutant of the mouse IL-4 (which is the 
essential tyrosine required for signalling), was able to bind to both type I and type II IL-
4 receptor complex with high affinity, and transiently block both IL-4 and IL-13 
signalling via the STAT6 pathway113 (Fig. 1.11b). 
 
Using an intranasal/intramuscular prime-boost immunisation strategy, the IL-13Rα2 
adjuvanted vaccine was shown to induce enhanced systemic HIV-specific CD8+ T cells 
with high avidity, broader cytokine and chemokine profiles and greater protective 
immunity122. This vaccine was also shown to induce excellent poly-functional mucosal 
CD8+ T cell responses in lung, genito-rectal nodes and Peyer’s patch122. Interestingly, 
the IL-4R antagonist adjuvanted vaccine was not only able to induce enhanced 
mucosal/systemic HIV-specific poly-functional CD8+ T cells with high avidity, but also 
induce robust HIV gag-specific IgG1 and IgG2a antibody responses, unlike IL-13Rα2 
adjuvanted vaccine where low antibody differentiation was detected113. Later studies in 
the laboratory showed that IL-4 and IL-13 levels at the vaccination site significantly 
modulate dendritic cell function. Specifically, using IL-13 and/or IL-4 inhibitor 
vaccines and IL-13-/- mice, Trivedi et al. have demonstrated that low level of IL-13 
and/or IL-4 induced elevated numbers of CD11b+ CD103- conventional dendritic cells 
(cDC) at the lung mucosae123 associated with the induction of high avidity, poly-
functional HIV-specific CD8+ T cells122. While high level of IL-13 and/or IL-4 
associated with rVV and rMVA vaccination induced reduced numbers of CD11b+ 
CD103- dendritic cells, but elevated recruitment of cross presenting CD11b- CD103+ 
dendritic cells which were directly linked to induction of poor quality HIV-specific 
CD8+ T cells123.  
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It is now established that HIV elite controllers, small number of individuals who 
naturally control HIV infection, possess high avidity HIV-specific CD8+ T cells as well  
as gag-specific antibodies with excellent ability to antibody differentiate124, 125, 126. The 
immune outcomes of observed specifically with IL-4R antagonist adjuvanted vaccine, 
in murine and macaque models (Khanna, Ranasinghe et al in preparation) indicate that 
this vaccine strategy may have high potential to be a successful HIV vaccine in the 
future. This lead to the important question, “what cells at the vaccination site produces 
IL-13 24 h post vaccination which are responsible for shaping the downstream immune 
outcomes?” which forms the basis of this thesis.  
 
1.7 Innate lymphoid cells (ILCs). 
ILCs are a newly identified heterogeneous population of cells with diverse activity in 
the immune system127, 128, 129, 130 (Fig. 1.12). However, these cells neither express 
lymphoid differentiation lineage markers which means they are lineage- nor antigen 
receptors which make them different from T cells and B cells23, 131, 132, 133, 134, 135, 136, 137. 
ILCs are classified as innate cells because they do not require the recombination 
activating genes RAG1 or RAG2 expression for their development, but since they are 
derived from the common lymphoid progenitor (CLP), they are considered as lymphoid 
cells138, and were named as innate lymphoid cells. The ILC population is generally 
divided into three distinct groups ILC1, ILC2, and ILC3 on the basis of similarity in 
their cytokine production, development requirements and phenotypic markers132, 139, 140, 
141. 
 
1.7.1 ILC2. 
ILC2 are classified based on their ability to produce T helper 2 (Th2) cell associated 
cytokines including IL-5, IL-9, IL-13 and IL-4132, 142 and respond to IL-25, IL-33 and  
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thymic stromal lymphopoietin (TSLP)127, 128, 129, 134, 135, 143, 144, 145. Currently, ILC2 are 
divided into three subsets according to receptors they express, IL-33R/ST2+, IL-25R+,  
or TSLPR+. ILC2 are known to express of CD127, IL-33R (ST2), ICOS, Sca-1, and 
lack other lineage markers146, 147, 148. The transcription factor GATA3 is often used as an 
intracellular marker to define ILC2149. ILC2 are thought to be tissue resident, and large 
populations are found in the intestine and lung137, 142, 146, 150, 151. Due to their Th2 
cytokine production, specifically IL-5, IL-9, IL-13, and IL-4; ILC2 have been well 
studies in type 2 inflammation, helminth infections and allergic asthma /inflammation 
134, 135, 136, 146, 147, 152 (Fig. 1.13). 
 
1.7.2 ILC1 and ILC3. 
ILC1 are defined based on their capacity to produce type 1 cytokines especially IFN-γ132, 
142. Some studies have also considered the conventional nature killer (NK) cells to be 
one subset of ILC1 128, 153. In fact, despite ILC1 and NK cells have the ability to produce 
IFN-γ and surface marker NKp46 (NKp44 in humans), they have several distinct 
features. Notably, NK cells are lineage+ cytotoxicity cells154 while ILC1 are lineage- 
non-cytotoxicity IFN-γ producing cells140, 155, 156. Secondly, NK cells are present in 
numerous sites as they recirculate between the blood and tissues, whereas ILC1 are 
thought to be tissue resident 140, 150, 156, 157, 158, 159, 160, 161, 162. ILC1 have been associated 
with the induction of immunity against intracellular bacteria and parasites 140, 155, 156, 163 
(Fig. 1.14).  
 
ILC3 were initially described in human tissues as mucosal-associated lymphoid cells 
that express NKp44 and produce IL-22164. Currently, three ILC3 subsets have been 
discovered based on the expression of various markers and cytokines, i) lymphoid tissue 
inducer (LTi) cells, ii) NKp46- ILC3 and iii) NKp46+ ILC3128, 165, 166. ILC3 can respond  
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to IL-1β and IL-23 and produce IL-17A, IL-22 and also IFN-γ, and these cells have 
been shown to play important roles in antibacterial immunity, chronic inflammation and  
tissue repair164, 167, 168, 169, 170 (Fig 1.15). Interestingly, according to the stimuli they 
encounter ILC3 have shown to be highly plastic163, 165, 166. 
 
1.7.3 ILC development. 
ILCs derive from bone marrow lymphoid progenitors (CLP)140, 171, 172, 173, 174, 175, 176, 177. 
Downstream of the CLP is the common innate lymphoid progenitor (CILP) which gives 
rise to all the different ILC subtypes and conventional NK cells but not T or B cells140, 
173, 178, 179. The transcriptional regulator inhibitor of DNA binding 2 (Id2) is essential for 
the CILPs to develop into common helper innate lymphoid cell progenitors (CHILP) 
(Fig. 1.16)134, 178, 180, and Id2 is expressed in high amounts in all ILC lineages149, 181. The 
CHILP consists of both promyeloid leukaemia zinc finger (PLZF)+ and PLZF- 
progenitors141, 182, and they give rise to all ILC subsets including the LTi cells140 but not 
conventional NK cells140. Further development and differentiation of ILC is driven by 
the activation of different transcription factors including GATA3, retinoic acid receptor-
related receptor-α (RORα), T-bet, and RORγt140, 141, 149, 183, 184, 185, 186, 187 (Fig. 1.16). 
 
1.7.4 ILC in inflammation and asthma. 
Since the discovery of ILC, these cells have been intensively studied in inflammation 
and asthma. Specifically, due to the expression of Th2 cytokines, ILC2 have been 
widely studied in inflammation 23, 132. ILC2 have been shown to respond to cytokines 
IL-25, IL-33, and TSLP and play an important role in type 2 inflammation by producing 
IL-5, IL-9, IL-13 and IL-4188, 189, 190, 191, 192, 193. In the lesions of atopic dermatitis 
patients, TSLP has been shown to expand ILC2s194, 195. Interestingly, studies have 
shown that ILC2 can also cooperate with dendritic cells and CD4+ T cells at mucosal  
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sites to regulate T cell responses in allergic airway inflammation condition196, 197. ILC1 
and IFN-γ producing ILC3 have also been reported to have the ability to induce  
inflammation in mice156, 170. Also, IFN-γ producing ILCs and IL-17A producing ILC3 
have been shown play a significant role in inflammatory bowel disease for example; 
Crohn’s disease155, 156, 170, 198. Specifically, IL-22 producing ILC3 have been shown to 
promote tissue repair and regeneration of inflamed intestine199. 
 
1.7.5 ILC in parasitic and helminth infections. 
ILC have also been shown to play an important role in immune responses against 
parasite and helminth infections. Specifically, IL-13 produced by ILC2 have been 
associated with inflammatory responses against extracellular helminth and parasitic 
infections23, 132, 200. For example, following infection with Nippostrongylus brasiliensis 
parasite in mice ILC2 have shown to be the dominant source of IL-13 apart from T 
cells136. In the context of cerebral malaria infection, exogenous IL-33 was shown to 
promote expansion of ILC2 that produced type-2 cytokines (IL-4, IL-5 and IL-13) and 
prevented the development of experimental cerebral malaria in mice with down 
regulation of inflammatory mediators such as IFN-γ, IL-12 and TNF-α201. Moreover, 
ILC2 have also been shown to play an important role in controlling filarial infection and 
related humoral responses202, 203. In the context of parasite and helminth infections, 
ILC1 are thought to be the main producers of protective IFN-γ and TNF-α at the early 
stage of infection (eg;  Toxoplasma gondii infection)204. 
 
1.7.6 ILC in viral infection. 
Although ILC have been studied intensively in inflammation and asthma conditions, not 
much attention has been given to ILC activation/function following viral infection. 
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Studies of influenza virus146, 191 and rhinovirus infection205 have shown that ILC2 play 
an important role in exacerbating asthma responses and tissue repair following viral 
infection146, 205. Interestingly, ILC also have been shown to play a role in HIV-1 
infection. For example, a recent study has shown that all ILC subsets were depleted 
during both acute and chronic HIV-1 infection and it was associated with epithelial gut 
breakdown206. Moreover, depletion of ILC3 in the GALT was also detected during 
acute SIV infection in macaques207. These findings suggest that ILC most likely play an 
important role in HIV-1 infection/pathology. Interestingly, how the different ILC 
derived cytokines profiles are modulated during viral infection/vaccination is poorly 
understood.  
 
1.7.7 Plasticity of ILCs. 
Recent studies into ILC, indicate that there is high plasticity between the different ILC 
subsets (Fig. 1.17), making it difficult to classify the different ILC subsets under 
different conditions. The first observations of high plasticity of ILC were observed 
between ILC1/ILC3, and ILC1/ILC3 can differentiate to each other under certain 
conditions163, 208, 209. Studies have shown that under IL-12 and IL-23 stimulation 
conditions subset of RORγt+ ILC3 can down regulate RORγt and increase T-bet and 
IFN-γ expression163, 166, 208, 209, 210. Moreover, Bernink et al have shown that CD127+ 
ILC1 can differentiate to ILC3 in the presence of IL-2, IL-23, and IL-1β209. Similarly, 
high plasticity of ILC2 has also been reported and ILC2 can differentiate to both ILC1 
and ILC3. For example, ILC2s isolated form human blood, when cultured in the 
presence of IL-1β were shown to express IL-12 receptor. Interestingly, when IL-12 was 
then added into the culture condition, these ILC2 were shown to express IFN-γ, and 
down regulate IL-5 and IL-13 expression211. In another study following influenza virus  
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infection, upon stimulation with IL-12 and IL-18, ILC2 were shown to down regulate 
GATA3 expression and convert to ILC1 and express IFN-γ212. Moreover, another study  
has shown that under IL-6 and transforming growth factor-β (TGF-β) culture condition, 
ILC2 can become ILC3-like cells and produce IL-17A213 (Fig. 1.17). 
 
These recent studies clearly indicate that the current understanding of ILC is limited, 
and the ILC regulation following inflammation and vaccination/infection could be 
vastly different. Specifically, ILC plasticity/regulation most likely is dependent on 
different stimulation conditions, which forms the basis of this thesis. 
 
1.8 Scope of this PhD thesis. 
Viral vector-based vaccine studies in our laboratory for the last decade have shown that 
IL-13 plays a crucial role in modulating the efficacy of a vaccine in a route dependent 
manner, where mucosal vaccination was shown to induce high avidity CD8 T cells with 
better protective efficacy by inducing lower IL-13, compare to systemic vaccination.  
Recent studies in the laboratory have shown that IL-13Rα2 and IL-4R antagonist 
adjuvanted viral vector-based vaccines that transiently inhibited IL-4/IL-13 activity at 
the vaccination site, induced excellent high avidity T cells with better protective 
efficacy, including excellent differentiated Gag-specific antibodies in mice and also in 
non-human primates. Thus, the main purpose of this study was to dissect the 
mechanisms of how IL-13 modulated T and B cell activity at the innate immune cell 
level, specifically at the ILC following pox viral vector-based vaccination. 
 
Hypotheses: 
1. ILC2s are the main source of IL-13 at the vaccination site 24h post vaccination, 
and route of vaccination and different adjuvants can significantly modulate ILC 
function at the vaccination site. 
2.  IL-25 plays a more predominant role in modulating ILC2 function following 
viral vector vaccination compared to IL-33. 
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3. ILC2-derived IL-13 and ILC1/ILC3-driven IFN-γ regulate the ILC balance at 
the vaccination site. 
 
Aims: 
1. Identify which cells are the predominant source of IL-13 at the vaccination site 
and how FPV-HIV unadjuvanted vaccine, FPV-HIV-IL-4R antagonist and FPV-
HIV-IL-13Rα2 adjuvanted vaccines that transiently inhibit IL-4 and/or IL-13, 
manipulate the different ILC subsets at the vaccination site. (Hypothesis 1) 
2. Evaluate the different ILC subsets recruited to lung and muscle following 
intranasal (mucosal) verses intramuscular (systemic) viral vector vaccination. 
(Hypothesis 1) 
3. Evaluate how FPV-IL-33BP and FPV-IL-25BP adjuvanted vaccines, that 
transiently block IL-25 and IL-33 respectively, modulate ILC activity at the 
vaccination site. (Hypothesis 2) 
4. Evaluate ILCs at the vaccination site in IL-13, IL-4 and STAT6 knockout mice 
following intranasal rFPV vaccination. (Hypothesis 3) 
5. Evaluate the expression of IL-4/IL-13 receptors (γC, IL-4Rα, IL-13Rα1, and 
IL-13Rα2) on ILC subsets and assess how they regulate IL-13 and IFN-γ at the 
vaccination site. (Hypothesis 3) 
 
Chapter 3 studies: Studies in our laboratory have found that IL-13 plays an important 
role in modulating anti-viral CD8+ T cells avidity, but it is still unclear which cells are 
the predominant source of IL-13 at the vaccination site. Also, since few studies have 
been focused on ILC in viral infection conditions, how different ILC subsets are 
modulated during this progress is still poorly understood. Thus, in Chapter 3, these 
questions were answered by evaluating ILC subsets following i.n./i.m. rFPV, IL-4R 
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antagonist and IL-13Rα2 adjuvanted vaccination (which block IL-4/IL-13 at the 
vaccination site) of BALB/c mice and evaluating the different ILC subsets at 0-7 days 
post vaccination. 
 
Chapter 4 studies: According to the current knowledge, ILC2 can be stimulated by IL-
33, IL-25 and TSLP. The surface receptors found on ILC2 can be different according to 
the tissue/mucosal compartment. For example: ST2/IL-33R+ ILC has been associated 
with lung, whereas TSLPR+ ILC2 in skin. However, the development of ILC2 and also 
ILC1/ILC3 following viral vaccination is poorly understood. Notably, whether there is a 
hierarchy in the expression of these different cytokines (specifically IL-25 vs IL-33) is 
not yet characterised. Thus, in this chapter rFPV co-expressing HIV antigen together 
with IL-25R binding protein (FPV-HIV-IL-25BP), or IL-33 binding protein (FPV-HIV-
IL-33BP), which can transiently sequester IL-25 or IL-33 at the vaccination site 
respectively were constructed. BALB/c mice were vaccinated intranasally with the 
adjuvanted vaccines or the unadjuvanted control vaccine (FPV-HIV), and the lung ILC 
profiles were evaluated 24 h post vaccination.  
 
Chapter 5 Studies: In this chapter, ILC function was further evaluated in IL-13-/-, IL-4-
/-, and STAT6-/- mice (permanent blockage of these cytokines) following i.n. rFPV 
vaccination and 24h post vaccination the lung ILC subsets and their cytokine expression 
were evaluated. In this chapter, transient verses permanent blockage of IL-4, IL-13 and 
STAT6 signalling and the potential role of IL-13 and IFN-γ in the context of antibody 
differentiation was assessed. 
 
Chapter 6 studies: IL-4 and IL-13 signalling via a common receptor system, however, 
the role of IL-13Rα2 is still well characterised. In this chapter the expression receptors 
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associated with IL-4 and IL-13 (γC, IL-4Rα, IL-13Rα1, and IL-13Rα2) on different 
ILC subsets were assessed in i) WT BALB/c mice following FPV-HIV unadjuvanted or 
IL-4R antagonist and IL-13Rα2 adjuvanted vaccines, and ii) IL-13-/-, IL-4-/-, and 
STAT6-/- mice, following FPV-HIV unadjuvanted vaccination using multicolour flow 
cytometry to understand how ILC2-derived IL-13 and ILC1/ILC3-derived IFN-γ are 
regulated, and test whether IL-13Rα2 is involved in this process. This was performed 
specifically, given that i) level of IL-13 expressed by ILC2 are known to be much lower 
than T cells and ii) in chapter 3 & 4 studies it was established that ILC2-driven IL-13 
modulated ILC1/ILC3 function. Thus, taken together IL-13Rα2 being the high affinity 
receptor for IL-13 (pM affinity) compared to IL-13Rα1 (nM affinity), it was 
hypothesised that IL-13Rα2 may be involved in ILC2-driven IL-13 regulation.  
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Chapter 2. 
General Materials and Methods. 
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2.1 Materials. 
Table 2.1 Medium. 
Name Component Source Catalogue number 
Complete 
RPMI medium 
RPMI-1640 medium (500 ml) 
HI-FCS (35 ml) 
1 M HEPES (10 ml) 
100 mM sodium pyruvate (10 ml) 
Pen-Strep (0.5 ml) 
β-mercaptoethanol (4 µl) 
Sigma 
GIBCO 
GIBCO 
GIBCO 
JCSMR 
Sigma 
R8758 
10099-133 
15630-080 
11360-070 
N/A 
M6250 
RPMI medium 
RPMI-1640 medium (500 ml) 
1 M HEPES (10 ml) 
Sigma 
GIBCO 
R8758 
15630-080 
Minimum 
Essential Medium 
Eagle (MEM) 
MEM 
5% (v/v) HI-FCS 
Sigma 
GIBCO 
M4655 
10099-133 
 
Table 2.2 Buffers and solutions. 
Name Component Source Catalogue number 
Lung tissue 
digestion buffer 
1 mg/ml Collagenase 
1.2 mg/ml Dispase 
5 Units/ml DNase 
Complete RPMI medium 
Sigma 
GIBCO 
Calbiochem 
Sigma 
C2139 
17105-041 
26095 
R8758 
Quadriceps 
muscle 
digestion buffer 
0.5 mg/ml Collagenase 
2.4 mg/ml Dispase 
5 Units/ml DNase 
Complete RPMI medium 
Sigma 
GIBCO 
Calbiochem 
Sigma 
C2139 
17105-041 
26095 
R8758 
Red blood cell 0.16 mM NH4Cl Sigma A-0171 
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lysis buffer 0.17 M Tris HCl (pH 7.65) MERCK 108382 
Brefeldin A 
(BFA) 
1:1000 working dilution in 
complete RPMI medium 
eBioscience 00-4506-51 
FACS buffer 
1X PBS 
2% FCS 
JCSMR 
GIBCO 
N/A 
10099-133 
IC-FIX buffer 1X IC-FIX BioLegend 420801 
IC-PERM 
buffer 
10% 10X IC-PERM 
90% dH2O 
eBioscience 
JCSMR 
00-8333-56 
N/A 
PFA 2% (w/v) PFA in PBS Sigma P-6148 
PBS 1X PBS Sigma D8537 
TrypLE  TrypLE EXPRESS GIBCO 1813304 
 
Table 2.3 Antibodies. 
Antibody Fluorochrome Clone Source 
Working 
dilution 
Lineage 
cocktail 
CD3 FITC 17A2 BioLegend 1:200 
CD19 FITC 6D5 BioLegend 1:100 
CD11b FITC M1/70 PharMingen 1:200 
CD11c FITC N418 BioLegend 1:100 
CD49b FITC HMα2 BioLegend 1:200 
FcεRI FITC MAR1 BioLegend 1:100 
CD45 APC/Cy7 30-F11 BioLegend 1:200 
ST2 PE DIH9 BioLegend 1:100 
ST2 PerCP/Cy5.5 DIH9 BioLegend 1:100 
Sca-1 APC D7 BioLegend 1:100 
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IL-25R APC 9B10 BioLegend 1:100 
CD127 
Brilliant Violet 
605 
A7R34 BioLegend 1:100 
NKp46 
Brilliant Violet 
421 
29A1.4 BioLegend 1:100 
TSLPR APC FAB5461A R&D 1:100 
GATA3 PerCP/Cy5.5 16E10A23 BioLegend 1:200 
IL-13 PE-eFlour 610 EBio13A eBioscience 1:100 
IL-4 
Brilliant Violet 
421 
11B11 BioLegend 1:100 
IL-17A Alexa Flour 700 TC11-18H10.2 BioLegend 1:100 
IFN-γ 
Brilliant Violet 
510 
XMG1.2 BioLegend 1:100 
IL-22 APC Poly5164 BioLegend 1:100 
Granzyme B PE 16G6 eBioscience 1:200 
IL-4Rα PE I015F8 BioLegend 1:200 
IL-13Rα1 PE 13MOKA eBioscience 1:200 
γ-c chain PE 554457 PharMingen 1:200 
IL-13Rα2 Biotin BAF539 R&D 1:50 
Streptavidin PE N/A BioLegend 1:200 
Isotype control PE EBio299Arm eBioscience 1:200 
FC block N/A 2.4G2 PharMingen 1:200 
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Table 2.4 Mice and vaccine strategies. 
Chapter Mice Vaccination strategies 
3 
BALB/c i.n. FPV-HIV 
BALB/c i.n. FPV-HIV-IL-4R antagonist 
BALB/c i.n. FPV-HIV-IL-13Rα2 
BALB/c i.m. FPV-HIV 
BALB/c i.m. FPV-HIV-IL-4R antagonist 
BALB/c i.m. FPV-HIV-IL-13Rα2 
4 
BALB/c i.n. FPV-HIV 
BALB/c i.n. FPV-HIV-IL-25BP 
5 
(Part I) 
BALB/c i.n. FPV-HIV 
IL-13-/- i.n. FPV-HIV 
IL-4-/- i.n. FPV-HIV 
STAT6-/- i.n. FPV-HIV 
5 
(Part II) 
BALB/c i.n. FPV-HIV 
BALB/c i.n. FPV-HIV-IL-4R antagonist 
BALB/c i.n. FPV-HIV-IL-13Rα2 
IL-13-/- i.n. FPV-HIV 
IL-4-/- i.n. FPV-HIV 
STAT6-/- i.n. FPV-HIV 
i.n. = intranasal, i.m. = intramuscular, IL-13-/- = IL-13 knockout mice, IL-4-/- = IL-4 
knockout mice, STAT6-/- = STAT6 knockout mice, FPV = Fowlpox virus 
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2.2 Methods. 
2.2.1 Mice.  
5-6 weeks old specific-pathogen free female WT BALB/c, IL-13-/-, IL-4-/- and STAT6-/- 
mice were obtained from the Australian Phenomics Facility, the Australian National 
University. Gene knockout mice (GKO) were from BALB/c background. All animals 
were maintained, and experiments were performed in accordance with the Australian 
NHMRC guidelines within the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes and in accordance with guidelines approved by the 
Australian National University Animal Experimentation and Ethics Committee (AEEC). 
Work in this thesis was conducted under the AEEC approved protocol numbers 
A2011/018, A2014/14, and A2017/15. 
 
2.2.2 Primary chicken embryo skin culture. 
All recombinant viruses used in this thesis were grown in primary chicken embryo skin 
cells (CES) which were stored in liquid nitrogen. Frozen CES were thawed rapidly and 
transferred to a 50 ml Falcon tube containing 30 ml MEM (as per described in Table 
2.1) at room temperature. Cells were centrifuged for 5 min at 1200 RPM (335×g) using 
a Beckman ALLEGRA X-12R centrifuge. The supernatant was discarded, 8 ml MEM 
was added, cells were transferred to T25 flask (Thermo Nunc EasYFlask) and cultured 
for 5 days at 37°C with 5% CO2 in a Forma Scientific water-jacketed incubator. Next 
CES cells were split into four T175 flasks. Specifically, medium was firstly removed, 
cells were washed once with 1×PBS.  Then1.5 ml TrypLE (as per described in Table 
2.2) was added and incubated for 5 min. Next 4.5 ml fresh MEM was added mixed 
thoroughly, and 1.5 ml cells were transferred to each T175 flask, followed by 30 ml 
fresh MEM. Cells were cultured for 5 days at 37°C with 5% CO2 in a Forma Scientific 
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water-jacketed incubator. CES cells were split every 5 days and maintained for no more 
than 8-9 splits.  
 
2.2.3 Recombinant virus stock preparation. 
To grow the recombinant fowl pox vector-based vaccine virus stocks used in this study 
(Table 2.4), CES cells were firstly cultured for 5 days as per described in 2.2.2, infected 
with rFPV at a rate of 0.5 multiplicity of infection for 1.5 h, and 20 ml fresh MEM was 
added and cultured for 4-5 days at 37°C with 5% CO2. To harvest virus, the infected 
cells were scraped from flasks and centrifuged for 10 min at 2300 rpm (1200×g) at 4°C 
using a Beckman ALLEGRA X-12R centrifuge. Then the cells were resuspended in 1 
ml sterile PBS and sonicated 3 times 15s on ice at 50 outputs using a Branson Sonifier 
450 until cell clumps were no longer visible. Then the virus stock was aliquoted and 
stored at -80°C. 
 
2.2.4 Recombinant virus titration. 
CES cells were subculture at 1×106 cells per well in a 6-well tissue culture plates 
(Costar Corning CellBIND Surface), incubated overnight at 37°C with 5% CO2. The 
rFPV stock was serially diluted (10 fold, from 10-1 to 10-6). 100 µl of each dilution was 
added to CES cells in 6-well plates respectively. Plates were incubated for 1.5 h at 37°C 
with 5% CO2 and gently shaken to make sure virus was evenly distributed in each well. 
Then 2 ml of fresh MEM was added to each well and cells were cultured for a further 4-
5 days. Next, media was removed, and cells were stained with 0.5 ml crystal violet (0.1% 
(w/v) in 20% ethanol) for 5 min to visualize plaques. Plaques were then counted, and 
the following equation was used to calculate the plaque forming unit (PFU)/ml: 
 𝑃𝑃𝑃𝑃𝑃𝑃/𝑚𝑚𝑚𝑚 = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 # 𝑝𝑝𝑚𝑚𝐴𝐴𝑝𝑝𝑝𝑝𝐴𝐴𝑝𝑝
𝑑𝑑𝑑𝑑𝑚𝑚𝑝𝑝𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑓𝑓𝐴𝐴𝑓𝑓𝑑𝑑𝑑𝑑𝐴𝐴 × 𝐴𝐴𝑑𝑑𝑚𝑚𝑝𝑝𝑚𝑚𝐴𝐴 𝑑𝑑𝑓𝑓 𝑑𝑑𝑑𝑑𝑚𝑚𝑝𝑝𝑑𝑑𝐴𝐴𝑑𝑑 𝐴𝐴𝑑𝑑𝐴𝐴𝑝𝑝𝑝𝑝 𝐴𝐴𝑑𝑑𝑑𝑑𝐴𝐴𝑑𝑑 
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2.2.5 Immunization.  
For both intranasal and intramuscular vaccination, 1×107 PFU of each vaccine was 
given to mice under mild isoflurane anaesthesia. The i.n. vaccines were given in 10-15 
µl per nostril (total 25-30µl volume) and i.m. vaccines 50 µl per quadriceps muscle. All 
vaccines were diluted in sterile PBS and sonicated 3 times 15s on ice at 50 outputs 
using a Branson Sonifier 450 prior to use. 
 
2.2.6 Preparation of lung lymphocytes.  
The mice were euthanised using cervical dislocation according to the approved AEEC 
guidelines. Lung tissues were removed and kept in complete RPMI medium on ice until 
processing. Single cell suspensions of lung tissues were prepared as described 
previously8, 122, 123. Specifically, the lung tissues were first cut into small pieces, and 
then enzymatically digested in 1 ml of lung digestion buffer containing 1 mg/ml 
collagenase (Sigma-Aldrich, St Louis, MO), 1.2 mg/ml Dispase (Gibco, Auckland, NZ), 
5 Units/ml DNase (Calbiochem, La Jolla, CA) in complete RPMI as indicated in Table 
2.2. During digestion, samples were vortexed every 10 min and incubated in a 37°C 
water bath for 45 min. The digested lung tissues were mashed and passed through a 100 
µm Falcon cell strainer. The strainer was then washed with complete RPMI medium 
and the resulting lung cell suspensions were centrifuged for 15 min at 1500 RPM 
(524×g) at 4°C using a Beckman ALLEGRA X-12R centrifuge. Next, the supernatants 
were removed, and cells were resuspended in 5 ml red blood cell lysis buffer containing 
0.16 mM NH4Cl and 0.17 M Tris HCl (pH 7.65) at room temperature for 3 min, then 30 
ml with RPMI medium was added to each sample and centrifuged at 1500 RPM (524×g) 
for 5 min at 4°C. It is noteworthy that to ensure maximum RBC lysis efficiency, the 
RBC lysis buffer was aliquoted and equilibrated to room temperature before use. The 
resulting supernatant was removed, washed once more and cells were resuspended in 
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RPMI medium and passed through sterile gauze to remove any remaining debris. Then 
the cells were washed twice using RPMI medium, and cell pellets were resuspended in 
0.5 ml complete RPMI medium. Lung cells from each sample were counted using a 
hemocytometer (Tiefe Depth Profondeur 0.100 mm). Next 2 × 106 cells per sample 
were plated in U-bottomed 96-well plates (Falcon) and were rested overnight (16 h) at 
37°C with 5% CO2 in a Forma Scientific water-jacketed incubator to allow the recovery 
of cell surface markers before performing the surface and intracellular staining122. 
 
2.2.7 Preparation of muscle lymphocytes. 
The mice were euthanised using cervical dislocation according to the approved AEEC 
guidelines. Quadriceps muscle was removed from both rear legs and kept in complete 
RPMI medium on ice until processing. To prepare quadriceps muscle single cell 
suspensions, muscle tissues were cut into small pieces and digested in buffer containing 
0.5 mg/ml Collagenase (Sigma-Aldrich, St Louis, MO), 2.4 mg/ml Dispase (Gibco, 
Auckland, NZ), and 5 Units/ml DNase (Calbiochem, La Jolla, CA) in complete RPMI 
as indicated in Table 2.2. 0.5 – 1 ml of digestion buffer was used to digest each muscle. 
During digestion, samples were gently vortexed every 10 min and incubated in a 37°C 
water bath for 45 min. The digested muscle tissues were gently passed through a 100 
µm Falcon cell strainer without mashing too much to avoid creating smaller debris. The 
strainer was then washed with RPMI medium and the resulting muscle cell suspensions 
were centrifuged for 15 min at 1500 RPM (524×g) at 4°C using a Beckman ALLEGRA 
X-12R centrifuge. The muscle cells were resuspended in RPMI medium and passed 
through sterile gauze similar to lung to further remove debris and then was washed 
twice with RPMI medium (Note that muscle tissues were not treated with RBC lysis 
buffer). Cell pellets were resuspended in 0.5 ml complete RPMI medium. Muscle cells 
for each sample were counted using a hemocytometer (Tiefe Depth Profondeur 0.100 
59 
 
mm). 3.5×105 cells per sample were plated into U-bottomed 96-well plates (Falcon) and 
were rested overnight (16 h) at 37°C with 5% CO2 in a Forma Scientific water-jacketed 
Incubator as per the lung samples. 
 
2.2.8 Surface and intracellular staining of ILC.  
Prior to staining, 1 × Brefeldin A (BFA) was added to each sample and incubated at 
37°C with 5% CO2 for 5 h to prevent cytokine release. Surface and intracellular staining 
were performed according to protocols established in our laboratory122. Specifically, 
cells were first centrifuged at 1300 RPM (524×g) for 2 min at 4°C using a Sigma 3K1S 
centrifuge and the supernatant was discarded, cells were washed twice with FACS 
buffer (Table 2.2). Next, Fc block antibodies were added, and cells were incubated on 
ice in the dark for 20 min. The cells were washed with FACS buffer and supernatant 
was discarded. Next, surface staining antibodies (dilution in Table 2.3) were added to 
each sample in a total volume of 40 µl and cells were incubated on ice in the dark for 40 
min. After surface staining, all cells were washed three times with FACS buffer and 
then resuspended in 100 µl IC-FIX buffer and incubated on ice in the dark for 10 min. 
After fixation, cells were washed with FACS buffer and permeabilised using IC-PERM 
buffer at room temperature in the dark for 10 min. Then the cells were centrifuged under 
the same condition and supernatant was discarded. The intracellular antibodies (dilution 
in Table 2.3) were diluted in IC-PERM buffer and were added to each sample in a total 
volume of 25 µl, cells were incubated on ice in the dark for 40 min and then washed 
twice with FACS buffer. The resulting cell pellets were resuspended in 100 µl 0.5% 
PFA and then transferred to cluster tubes and run on a BD LSR Fortessa on the same 
day of staining. From each lung sample 1400000 events were acquired, and 200000 
events were acquired for each quadriceps muscle sample. Data were analysed using 
Tree Star FlowJo software version 10.0.7 for Windows. 
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2.2.9 General ILC gating strategy. 
2.2.9.1 Fluorescence minus one (FMO) and single colour controls. 
In this thesis to assess the different ILC populations and cytokine expression (Fig. 2.1 
and 2.2) single colour controls and fluorescent minus one (FMO) controls were used to 
setup the gates. The red boxes indicate the positive populations.  
 
2.2.9.2 Lung ILC gating strategy. 
Lung samples from each experiment were stained as described in 2.2.6. The ILC were 
gated as indicated in Fig. 2.3. Firstly, CD45+ cells were gated from total lung cells, and 
then from CD45+ cells lymphocytes were gated as FSClow SSClow cells. Next within the 
lymphocyte gate, lineage+ cells were gated out using the FITC-conjugated lineage 
cocktail (as indicated in Table 2.3 and Table 2.5). In the lineage- population, ILC2 
were identified as lineage- ST2/IL-33R+ cells. In this study Sca-1 and CD127 (IL-7R) 
expression profiles were also evaluated on lineage- cells.  
 
2.2.9.3 Quadriceps muscle ILC gating strategy. 
After muscle tissues were digested and stained as per described in 2.2.7 and 2.2.8, 
CD45+ cells and lymphocytes were gated from total muscle cells. Next, within the 
lymphocyte gate, ILC2 were identified as Lineage- IL-25R+ cells (as no ST2/IL-33R+ or 
TSLPR+ cells were detected in muscle). Then the lineage- ST2/IL-33R- cells (ILC1& 
ILC3) were stained with NKp46 (Fig. 2.4). 
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2.2.10 Calculation of cell numbers. 
The ILC subsets were characterized using the gating strategies described in section 2.2.8. 
In this study, the cell numbers were back calculated to CD45+ gate as there was no 
significant differences in the total CD45+ cells among different mice groups or vaccines 
groups tested. This was performed by back-calculating cell numbers of each ILC 
subsets to CD45+ population and then normalizing to 1×106 cells. The following 
equation was used to calculate the cell numbers: 
𝐶𝐶𝐴𝐴𝑚𝑚𝑚𝑚 𝑑𝑑𝑝𝑝𝑚𝑚𝑛𝑛𝐴𝐴𝐴𝐴 =  𝑋𝑋
𝐶𝐶𝐶𝐶45+ 𝑓𝑓𝐴𝐴𝑚𝑚𝑚𝑚 𝑑𝑑𝑝𝑝𝑚𝑚𝑛𝑛𝐴𝐴𝐴𝐴  × 1 × 106 
X = the absolute cell numbers in the specific gate. 
 
2.2.11 Statistical analysis.  
Data in this thesis, n = 3 to 6 mice per group were used and all experiments were 
repeated at least three times, and 24h experiments were repeated six times.  Data are 
represented as the mean and standard deviation (s.d.). Statistical analysis was performed 
using GraphPad Prism software (version 6.05 for Windows). One-way ANOVA using 
Tukey’s multiple comparisons test and unpaired T-test were used. The P-values are 
denoted as: ns - p≥0.05, * - p<0.05, ** - p<0.01. *** - p<0.001, **** - p<0.0001.  
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Chapter 3. 
Vaccination route can significantly alter the innate lymphoid 
cell subsets: A feedback between IL-13 and IFN-γ. 
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3.1 Abstract. 
This study demonstrates that the efficacy of a vaccine is influenced by the cytokines 
produced by the innate lymphoid cells (ILC) recruited to the vaccination site and is 
vaccine route and adjuvant dependent. Intranasal virus vaccination induced ST2/IL-
33R+ ILC2 in lung, while intramuscular vaccination induced exclusively IL-25R+ ILC2 
in muscle. Interestingly, a larger proportion of IL-13+ ILC2s were detected in muscle 
following i.m. viral vector vaccination compared to lung post i.n. delivery. These 
observations revealed that, ILC2 were the main source of IL-13 at the vaccination site 
(24h post vaccination) responsible for inducing T cells of varying avidities. Moreover, 
recombinant fowlpox viral vector-based vaccines expressing adjuvants that transiently 
block IL-13 signalling at the vaccination site using different mechanisms (IL-4R 
antagonist or IL-13Rα2 adjuvants), revealed that the level of IL-13 present in the milieu 
also significantly influenced IFN-γ, IL-22 or IL-17A expression by ILC1/ILC3. 
Specifically, an early IL-13 and IFN-γ co-dependency at the ILC level may also be 
associated with shaping the downstream antibody responses, supporting the notion that 
differentially regulating IL-13 signalling via STAT6 or IL-13Rα2 pathways can modify 
ILC function and the resulting adaptive T and B cell immune outcomes reported 
previously. Moreover, unlike chronic inflammatory or experimentally induced 
conditions, viral vector vaccination induced uniquely different ILC profiles (i.e. 
expression of CD127 only on ILC2 not ILC1/ILC3; expression of IFN-γ in both 
NKP46+ and NKp46- ILCs). Collectively, data highlight that, tailoring a vaccine 
vector/adjuvant to modulate the ILC cytokine profile according to the target pathogen, 
may help design more efficacious vaccines in the future. 
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3.2 Introduction. 
Innate lymphoid cells (ILCs) are a recently identified class of immune cells which do 
not express antigen receptors nor surface markers characteristic of other immune cells, 
i.e. lineage negative214. ILCs are known to play a multi-factorial role at the mucosae16,  
for example, in tissue remodelling23, allergy and inflammation146, 215, Crohn’s disease214, 
and immunity towards helminth and intracellular parasitic infections146, 215, 216. ILCs are 
thought to develop from a common lymphoid progenitor214, 217, and according to the 
transcription factors and cytokines they express, ILC have been broadly classified into 
three main categories. ILC1 respond to IL-12, IL-18 and IL-15 and express transcription 
factor T-bet, interferon (IFN)-γ and tumour necrosis factor (TNF)-α. ILC2 subsets are 
characterised by surface receptors IL-33R+ (ST2+), IL-25R+ (IL-17RB+) or TSLPR+ and 
can be stimulated by IL-33, IL-25 (IL-17E) or thymic stromal lymphopoietin (TSLP), 
respectively. Activated ILC2 express GATA3, IL-13, IL-5, IL-9 or IL-4.  In contrast, 
ILC3 respond to IL-1β and IL-23 and express RORγt, IL-22 and IL-17A90, 214, 217. 
However, recent studies indicate strong plasticity between ILC2, ILC1 and ILC3 
subsets according to the tissue environment and the external stimuli they encounter209, 
218, 219. 
 
Studies have shown that influenza virus146, 191 and rhinovirus infection stimulate ILC2 
IL-13 expression and exacerbate asthma responses205, and HIV infection causes an 
irreversible loss of ILC function during acute infection220. However, how different ILC 
subsets are modulated during viral infection or vaccination and influence vaccine-
specific immunity is poorly understood. A range of recombinant viruses, including 
Avipoxviruses (canarypox and fowlpox viruses) used in the HIV RV144 Thai trial221, 
Modified Vaccinia Ankara (MVA) and Adenovirus-5 are being developed as vectors to 
deliver vaccines for human diseases, However, the mechanisms by which these different 
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vaccine vectors modulate innate immunity is not fully understood. MVA is known to 
stimulate TLR2, TLR6 and NALP3 inflammasome pathways, with vigorous IFN-β and 
IL-1β expression by macrophages222. While ILC2 IL-13 expression licences CD11b+ 
CD103- conventional dendritic cells to stimulate CD4+ T helper 2 (Th2) responses223. 
However, the influence of ILC interacting with professional antigen presenting cells in 
stimulating of antiviral Th1 immunity is not known. Thus, understanding how these 
vaccine vectors interact with the innate immune response and influence resulting 
adaptive immunity is paramount for developing efficacious vaccine technologies in the 
future. 
 
Our previous studies, have revealed that i) recombinant poxvirus HIV-1 antigen 
vaccines delivered via the mucosa induce high avidity, poly-functional HIV-specific 
CD8+ T cells with reduced IL-4 and IL-13 expression77, ii) IL-13Rα2 and IL-4R 
antagonist adjuvanted vaccines transiently blocking IL-13 and/or IL-4 signalling at the 
vaccination site induce higher avidity/multi-functional HIV specific effector/memory 
CD8+ T cells with improved CD8+ T cell mediated protective efficacy113, 122 and iii) IL-
4R antagonist adjuvant vaccine also induces HIV gag-specific IgG1 and IgG2a 
antibodies113. (The IL-13Rα2 adjuvanted vaccine co-expresses HIV antigens together 
with soluble IL-13Rα2 and can block IL-13 activity at the vaccination site.  Whereas the 
IL-4R antagonist adjuvanted vaccine co-expresses HIV antigens and C-terminal 
deletion mutant of the mouse IL-4 without the essential tyrosine required for signalling, 
which can bind to both type I and type II IL-4 receptor complexes with high affinity, 
and transiently block both IL-4 and IL-13 signalling at the vaccination site)123. 
Interestingly, the responses observed with the adjuvanted vaccines in mice were similar 
to what has been reported for elite controllers who naturally control HIV infection and 
do not progress to clinical AIDS126, 224, 225. While we have gained some understanding of 
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how IL-4/IL-13 regulates CD8+ T cell avidity at the adaptive immune level78, 79, 226, it is 
still unclear which cells in the innate immune compartment are involved in IL-4, IL-13 
and IFN-γ expression and/or regulation at the vaccination site, responsible for the 
downstream T and B cell outcomes.   
 
3.3 Materials and Methods. 
3.3.1 Mice and immunisation. 
5-6 weeks old pathogen free female WT BALB/c mice were obtained from the 
Australian Phenomics Facility, the Australian National University, and were maintained 
and handled under protocols indicated in 2.2.1. 1×107 PFU unadjuvanted FPV-HIV, 
FPV-HIV-IL-4R antagonist adjuvanted, and FPV-HIV-IL-13Rα2 adjuvanted vaccines 
were administered to WT BALB/c mice (n = 3 to 6 per group) intranasally or 
intramuscularly, under mild isoflurane anaesthesia as per described in 2.2.5. Lungs were 
harvested in 2 ml of complete RPMI at 24 h, 3 days, and 7 days post immunisation, and 
single cell suspension was prepared as per described in 2.2.6. Quadriceps muscles were 
harvested in 2 ml of complete RPMI at 24 h post immunisation, and single cell 
suspension was prepared as per described in 2.2.7. 
 
3.3.2 Surface and intracellular staining. 
Surface and intracellular staining were performed as per described in 2.2.8 using 
antibodies listed in Table 2.3. Specifically, 
ILC2 staining: APC/Cy7-conjugated anti-mouse CD45, and FITC-conjugated lineage 
cocktail were used to identify lineage- cells. PE-conjugated anti-mouse ST2/IL-33R, 
APC-conjugated anti-mouse IL-25R, APC-conjugated anti-mouse TSLPR were used to 
identify the different ILC2 subsets. APC-conjugated anti-mouse Sca-1, Brilliant Violet 
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605-conjugated anti-mouse CD127, and PerCP/Cy5.5-conjugated anti-mouse GATA3 
(stained intracellularly) were used to further confirm that the CD45+ lineage- ST2/IL-
33R+ cells were true ILC2s. Brilliant Violet 421-conjugated anti-mouse IL-4 and PE-
eFlour 610-conjugated anti-mouse IL-13 were used to evaluate intracellular expression 
of these cytokines in ILC2s. 
 
ILC1/3 staining: APC/Cy7-conjugated anti-mouse CD45, and FITC-conjugated lineage 
cocktail were used to identify lineage- cells. PE-conjugated anti-mouse ST2/IL-33R, 
Brilliant Violet 421-conjugated anti-mouse CD335 (NKp46), and Brilliant Violet 605-
conjugated anti-mouse CD127 were used to identify ILC1/3 populations. Brilliant 
Violet 510-conjugated anti-mouse IFN-γ, APC-conjugated anti-mouse L-22, and Alexa 
Fluor 700-conjugated anti-mouse IL-17A were used to evaluate intracellular expression 
of these cytokines in ILC1 and ILC3. PerCP/Cy5.5-conjugated anti-mouse GATA3 was 
also used to make sure ILC1/3 subsets did not contain any ILC2.  
 
Granzyme B staining: In this thesis, ILC1 and ILC3 were divided into lineage- ST2/IL-
33R- NKp46+ or lineage- ST2/IL-33R- NKp46- cells, since NKp46 is also a common 
marker of conventional NK cells. Thus, to confirm that lineage- ST2/IL-33R- NKp46+ 
population did not contain any conventional NK cell contamination, a Granzyme B 
staining was performed (Note that Granzyme B is expressed in conventional NK cells, 
but are not expressed in ILC).  In NK cell staining, APC/Cy7-conjugated anti-mouse 
CD45, and FITC-conjugated lineage cocktail were used to identify lineage+/- cells. 
Brilliant Violet 421-conjugated anti-mouse CD335 (NKp46) and PE-conjugated anti-
mouse Granzyme B were used to identify conventional NK cells. 
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All ILC subsets were gated as per described in 2.2.9. Granzyme B expression in 
conventional NK cells and lineage- NKp46+/- cells was assessed using gating strategies 
described in the results section. 
 
3.4 Results. 
3.4.1 Intranasal vaccination induces lineage- ST2/IL-33R+ ILC2s 
expressing IL-13 at the lung mucosae and IL-4R antagonist/IL-13Rα2 
adjuvanted vaccines inhibit this activity. 
Previous studies in our laboratory have shown that 24 h post intranasal IL-4R antagonist 
and IL-13Rα2 adjuvanted vaccination can alter IL-4/IL-13 signalling at the vaccination 
site122 and this directly influences the activity of antigen presenting cells (APC) at the 
lung mucosae resulting in high avidity CD8+ T cell mediated immunity123. In this study, 
we have embarked upon understanding how the expression of IL-4 and/or IL-13 by ILC 
at the lung mucosae can modulate adaptive immune outcomes following intranasal 
vaccination using i) FPV-HIV unadjuvanted, ii) FPV-HIV-IL-4R antagonist and iii) 
FPV-HIV-IL-13Rα2 adjuvanted vaccines. Firstly, 12h to 7 days post i.n. vaccination the 
lung ILC2 were evaluated as described in 2.2.6.1 (Fig. 3.1a). ILC2 were gated as 
CD45+ FSClow, SSClow, lineage- and ST2/IL-33R+ cells (Fig. 2.1).  
 
At 12 h although no differences in the ST2/IL-33R+ ILC2 percentages were detected, 
significant differences were detected 24 h post vaccination (Fig. 3.1b). Interestingly, 
compared to the control unadjuvanted vaccine, the IL-13Rα2 adjuvanted vaccine 
sequestering IL-13 in the cell milieu, showed significant suppression of ILC2 at the 
lung mucosae 24 h to 7 days post vaccination, suggesting a requirement for free IL-13 
in maintaining ILC2 cells. In contrast, IL-4R antagonist vaccine which blocked both IL-
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4 and IL-13 cell-signalling via IL-4R/STAT6 pathway showed significantly elevated 
percentages of ST2/IL-33R+ ILC2, 24 h post vaccination compared to the other two 
vaccines tested (Fig. 3.1b). It is noteworthy that very low ILC2 were detected in naïve 
mice lung, average 0.074% (Fig. 3.2) vs unadjuvanted vaccinated 0.29%. 
 
When IL-13 expression was evaluated in the lung lineage- ST2/IL-33R+ ILC2, higher 
IL-13 expression was detected in mice that received the unadjuvanted vaccine compared 
to the IL-4R antagonist or IL-13Rα2 vaccines (p< 0.0001) (Fig. 3.1c). Interestingly, 
although IL-4R antagonist and IL-13Rα2 vaccines activated different overall 
percentages of ST2/IL-33R+ ILC2 at the lung mucosae, both vaccines significantly 
inhibited IL-13 expression by ST2/IL-33R+ ILC2, at 24 h to 7 days post vaccination 
compared to the control unadjuvanted FPV-HIV vaccine (Fig. 3.1d). It is noteworthy 
that the trend of ST2/IL-33R+ IL-13+ cells observed overtime presented as percentage or 
total cell number were similar (Fig. 3.1d). In all three vaccinated groups, lineage- 
ST2/IL-33R+ ILC2 did not express IL-4 at any of the time points tested. Furthermore, 
lineage- ST2/IL-33R+ ILC2 obtained from unimmunised controls (Fig. 3.2) and 
importantly the lineage+ ST2/IL-33R+ cells obtained from vaccinated and non-
vaccinated groups (Fig. 3.3) also did not show any expression of IL-4 or IL-13. This 
was further confirmed by staining each lineage marker separately for IL-4 and IL-13 
(Fig. 3.4), and data clearly indicated that the lineage- ST2/IL-33R+ cells did not contain 
any contaminating mast cells or basophils. 
 
Stem cell marker Sca-1 expression227 was found to be inversely related to the 
percentage of CD45+ lineage- ST2/IL-33R+ ILC2 over time regardless of adjuvant 
treatment (Fig. 3.1e & 3.1f). Few Sca-1+ ILC2 were detected at 12 h in all three vaccine  
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groups tested, however by 24 h post vaccination CD45+ lineage- ST2/IL-33R+ ILC2s 
following IL-4R antagonist adjuvanted vaccine showed significantly elevated Sca-1 
expression compared to the other two vaccines. Although Sca-1- subset did not express 
IL-13, the Sca-1+ ST2/IL-33R+ ILC2 subset was positive for IL-13 in the unadjuvanted 
vaccine, while the IL-4R antagonist and IL-13Rα2 adjuvanted vaccines showed 
complete inhibition of IL-13 expression (Fig. 3.1h & 3.1g). These results indicated that 
Sca-1 is a general activation marker for ST2/IL-33R+ ILC2, and not necessary 
dependent on IL-13 expression.  
 
3.4.2 Expression of IFN-γ and IL-22 by NKp46+ ILC subset is 
differentially regulated following FPV-HIV-IL-13Rα2 and FPV-HIV-
IL-4R antagonist vaccination at the lung mucosae. 
According to the micro environment/cell milieu, high plasticity of ILC1 and ILC3 has 
been observed and classifying ILC1 and ILC3 according to their cell surface marker 
expression has been a difficult task142, 228, 229, 230. Thus, in this viral vector-based 
vaccination study, for better clarity the ILC subsets (ILC1 and ILC3) were identified as 
lineage- NKp46+ ILC and lineage- NKp46- ILC and assessed according to their 
cytokines production. Unlike the lineage- ST2/IL-33R+ cells that were CD127+ and 
GATA3+, 99.7% of the lineage- ST2/IL-33R- cells were found to be CD127- and 
GATA3- (Fig. 2.1). Furthermore, to confirm that the ILCs were not conventional NK 
cells, granzyme B expression was evaluated on the lineage+ NKp46+ and lineage- 
NKp46+ subsets (Fig. 3.5b & d), as expected in the lineage- population, no granzyme B 
was detected (Fig. 3.5b), whereas in the lineage+ NKp46+ population, both IFN-γ and 
granzyme B were detected (Fig. 3.5e). These data clearly confirmed that no  
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conventional NK cells were present in the lineage- population. Interestingly, 24 h post 
vaccination, the IL-4R antagonist vaccinated group showed elevated IFN-γ expression  
by the lineage+ NKp46+ (conventional NK cells) subset (~22%) compared to the control 
unadjuvanted (~15%) or IL-13Rα2 adjuvanted vaccine groups tested (~7%) (Fig. 3.6). 
Interestingly, very low NKp46+ ILC were detected in naïve mice lung, average 0.21% 
(Fig. 3.2) vs unadjuvanted vaccinated 3.95%. 
 
Lineage- ST2/IL-33R- NKp46+ ILC were detected in all three vaccine groups tested 24 h 
post vaccination (Fig. 3.7b) but the highest percentage was detected in the IL-4R 
antagonist vaccinated group (p < 0.0001) (Fig. 3.7b). In the context of IFN-γ expression 
by NKp46+ ILC, control unadjuvanted and IL-4R antagonist vaccinated groups showed 
similar IFN-γ expression profile compared to the lower IL-13Rα2 adjuvanted vaccine 
group, although only control unadjuvanted showed statistical significance to IL-13Rα2 
adjuvanted vaccine (p < 0.01) (Fig. 3.7c-d). Unlike IFN-γ, the IL-22 production by 
NKp46+ ILCs was significantly reduced in both IL-4R antagonist and IL-13Rα2 vaccine 
groups compared to the control at 24 h (p < 0.0001) (Fig. 3.7e).  However, at all time 
points tested the level of IL-22 was much lower in animals that received FPV-HIV-IL-
13Rα2 vaccine (Fig. 3.7f). 
 
3.4.3 FPV-HIV-IL-4R antagonist vaccine significantly increases IFN-γ 
production by NKp46- ILC at the lung mucosae. 
When the lineage- ILCs were assessed post i.n. delivery, most of the cells were found to 
be ST2/IL-33R- NKp46- ILCs (Fig. 3.8a). There was no significant difference in the 
percentages of NKp46- ILC numbers between the vaccine groups tested, except for 24 h 
time point (Fig. 3.8b). Next when cytokine expression was evaluated in ST2/IL-33R-  
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NKp46- ILCs, significantly elevated IFN-γ expression was detected in FPV-HIV-IL-4R 
antagonist group compared to the control unadjuvanted group and FPV-HIV-IL-13Rα2 
group from 24 h to 7 days post vaccination (p < 0.0001 – 0.01) (Fig. 3.8c, d). At 24 h 
post vaccination, similar to the ST2/IL-33R- NKp46+ ILC, IL-22 production by ST2/IL-
33R- NKp46- ILC was significantly lower in both FPV-HIV-IL-4R antagonist and FPV-
HIV-IL-13Rα2 adjuvanted vaccine groups compared to the control unadjuvanted group 
(Fig. 3.8e, f).  
 
3.4.4 Intramuscular vaccination induces exclusive lineage- IL-25R+ 
ILC2 subset at the vaccination site. 
Next when BALB/c mice were immunised intramuscularly (i.m.) and ILC2s were 
evaluated, no IL-33R+ ILC2s were detected in muscle and only IL-25R+ ILC2 were 
observed (Fig. 3.9a&b). ST2/IL-33R+ ILC2s were only found in the lung following 
intranasal vaccination (Fig. 3.10). However, no IL-25R+ or IL-33R+ ILC2s were 
detected in naïve quadriceps muscle of BALB/c mice (Fig. 3.11). More interestingly, 
compared to the other two vaccines FPV-HIV-IL-4R antagonist vaccine significantly 
suppressed the IL-25R+ ILC2s while FPV-HIV-IL-13Rα2 adjuvanted vaccine 
significantly increased the IL-25R+ ILC2 number (Fig. 3.9c). When IL-13 expression by 
lineage- ST2/IL-33R- IL-25R+ ILC2 subset was assessed, significantly higher IL-13 
expression was detected in control unadjuvanted vaccines compared to the FPV-HIV-
IL-4R antagonist and FPV-HIV-IL-13Rα2 adjuvanted vaccines (p < 0.0001) (Fig. 3.9d). 
Interestingly, although FPV-HIV-IL-4R antagonist and FPV-HIV-IL-13Rα2 adjuvanted 
vaccines activated different overall percentages of IL-25R+ ILC2 numbers, both 
vaccines were able to significantly down-regulate the IL-13 production by IL-25R+ 
ILC2 compared to control unadjuvanted FPV-HIV vaccine (Fig. 3.9e). In all vaccine 
groups tested, no IL-4 production was detected in IL-25R+ ILC2. 
a b c
d e
F
ig
.
3.
9.
E
va
lu
at
io
n
of
IL
C
2
su
bt
yp
es
an
d
cy
to
ki
n
es
th
ey
ex
p
re
ss
in
th
e
qu
ad
ri
ce
p
s
m
us
cl
e
24
h
po
st
in
tr
am
us
cu
la
r
va
cc
in
at
io
n
.
B
A
L
B
/c
m
ic
e
w
er
e
im
m
un
iz
ed
in
tr
am
us
cu
la
rl
y
w
it
h
F
P
V
-H
IV
,
FP
V
-H
IV
-I
L
-4
an
ta
go
ni
st
,
an
d
F
PV
-H
IV
-I
L
-1
3R
α2
va
cc
in
es
an
d
th
e
pe
rc
en
ta
ge
of
IL
C
2
in
m
us
cl
e
ce
ll
s
w
as
ev
al
ua
te
d
24
h
po
st
va
cc
in
at
io
n
(n
ot
e
th
at
no
S
T
2/
IL
-3
3R
+
IL
C
2
w
er
e
de
te
ct
ed
in
m
us
cl
e)
.I
n
th
is
st
ud
y
IL
C
2
ce
ll
s
w
er
e
id
en
ti
fi
ed
as
C
D
45
+
F
S
C
lo
w
SS
C
lo
w
li
ne
ag
e-
S
T
2/
IL
-3
3R
-
IL
-2
5R
+
ce
lls
us
in
g
fl
ow
cy
to
m
et
ry
(a
&
b
).
T
he
FA
C
S
pl
ot
s
ar
e
re
pr
es
en
ta
ti
ve
of
ea
ch
va
cc
in
at
io
n
(b
)
an
d
th
e
co
ll
ec
te
d
da
ta
ar
e
pr
es
en
te
d
in
gr
ap
h
(c
).
T
he
ex
pr
es
si
on
of
IL
-1
3
by
IL
-2
5R
+
IL
C
2s
w
er
e
al
so
as
se
ss
ed
(d
&
e)
.T
he
gr
ap
hs
re
pr
es
en
tm
ea
n
an
d
st
an
da
rd
de
vi
at
io
n
(s
.d
.)
.T
he
p-
va
lu
es
w
er
e
ca
lc
ul
at
ed
us
in
g
G
ra
ph
P
ad
P
ri
sm
so
ft
w
ar
e
(v
er
si
on
6.
05
fo
r
W
in
do
w
s)
.*
P<
0.
05
,*
*p
<
0.
01
,*
**
*P
<
0.
00
01
(o
ne
-w
ay
A
N
O
V
A
).
F
or
ea
ch
ti
m
e
po
in
te
xp
er
im
en
ts
w
er
e
re
pe
at
ed
th
re
e
ti
m
es
.
F
ig
.3
.1
0.
S
ta
in
in
g
of
lu
n
g
ti
ss
u
e
fo
r
d
if
fe
re
n
t
IL
C
2
su
b
se
ts
.
C
el
ls
w
er
e
ga
te
d
fr
om
C
D
45
+
an
d
ly
m
ph
oc
yt
es
as
sh
ow
n
in
su
pp
le
m
en
ta
ry
F
ig
ur
e
1
an
d
li
ne
ag
e-
S
T
2/
IL
-3
3R
+
,
li
ne
ag
e-
IL
-2
5R
+
,
an
d
li
ne
ag
e-
T
S
L
P
R
+
lu
ng
IL
C
2
su
bs
et
s
w
er
e
ev
al
ua
te
d
24
h
po
st
F
PV
-H
IV
im
m
un
iz
at
io
n.
F
ol
lo
w
in
g
rF
P
V
im
m
un
iz
at
io
n,
al
l
lu
ng
IL
C
2s
w
er
e
fo
un
d
to
be
S
T
2/
IL
-3
3R
+
.N
um
be
rs
on
FA
C
S
pl
ot
s
re
pr
es
en
tc
el
lp
er
ce
nt
ag
e.
F
ig
.
3.
11
.
E
va
lu
at
io
n
of
d
if
fe
re
n
t
IL
C
2
su
b
se
ts
in
n
aï
ve
m
ic
e
q
u
ad
ri
ce
p
s
m
u
sc
le
.
C
el
ls
w
er
e
ga
te
d
fr
om
C
D
45
+
an
d
ly
m
ph
oc
yt
es
as
pe
r
de
sc
ri
be
d
in
m
at
er
ia
ls
an
d
m
et
ho
ds
.
N
o
or
ex
tr
em
el
y
lo
w
S
T
2/
IL
-3
3R
+
(0
.0
08
%
)
an
d
IL
-2
5R
+
(0
.0
11
%
)
IL
C
2
ce
ll
s
w
er
e
de
te
ct
ed
in
qu
ad
ri
ce
ps
m
us
cl
e
in
na
ïv
e
B
A
L
B
/c
m
ic
e
(a
).
V
er
y
lo
w
N
K
p4
6+
IL
C
(1
8.
3%
)
w
er
e
de
te
ct
ed
in
qu
ad
ri
ce
ps
m
us
cl
e
in
na
ïv
e
B
A
L
B
/c
m
ic
e
(b
).
a b
103 
 
3.4.5 Intramuscular vaccination induces uniquely different lineage- 
NKp46- and NKp46+ ILC subsets at the vaccination site. 
When lineage- IL-25R- (also ST2/IL-33R-) NKp46+ and NKp46- ILC subsets were 
evaluated 24 h post vaccination, the FPV-HIV-IL-4R antagonist vaccinated group 
showed very low NKp46+ ILC and elevated percentage of NKp46- ILC compared to the 
control unadjuvanted and FPV-HIV-IL-13Rα2 vaccines (Fig. 3.12a). Interestingly, in 
naïve mice very low NKp46+ ILC were detected compared to unadjuvanted vaccinated, 
average 2.65% (Fig. 3.11) vs 86.4%. When cytokine profiles were evaluated in these 
two subsets, significantly elevated IFN-γ and IL-22 expression was detected in NKp46+ 
ILC obtained from FPV-HIV-IL-13Rα2 adjuvanted vaccinated group compared to the 
IL-4R antagonist vaccine group (p < 0.05- 0.0001) (Fig. 3.12b & Fig. 3.13). Also, the 
percentage of IL-25R- NKp46+ ILC that expressed IFN-γ (p < 0.001) and IL-17A (p < 
0.01) was significantly higher in FPV-HIV-IL-13Rα2 adjuvanted group compared to the 
control (Fig. 3.12b & Fig. 3.13a). Overall, the HIV-IL-13Rα2 vaccinated group showed 
elevated percentage of lineage- IL-25R- NKp46+ ILC expressing IFN-γ, IL-22 and IL-
17A compared to the other two groups tested.  
 
Unlike IL-22 and IL-17A that was detected in both lineage- IL-25R- NKp46+ and 
NKp46- ILC subsets, no IFN-γ expression was detected IL-25R- NKp46- ILC. Although 
there was no significant difference in IL-22 and IL-17A production by NKp46- ILC 
subsets between control unadjuvanted and FPV-HIV-IL-4R antagonist vaccinated 
groups, FPV-HIV-IL-13Rα2 adjuvanted vaccinated group showed significantly reduced 
percentage of NKp46- ILC expressing IL-17A compared to the other two vaccine 
groups tested (p < 0.001 – 0.0001) (Fig. 3.14). No NKp46+ or NKp46- ILC subsets were 
positive for both IL-22 and IL-17A. 
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3.5 Discussion. 
In this study, our approach of characterising lineage- ILC subsets based principally upon 
cytokine expression without preconceived expectations of cell surface markers have 
shown that ILC induced following viral vector vaccination are uniquely different to 
what has been reported under experimentally induced or chronic inflammation 
conditions. Following rFPV vaccination although ILC2 were found to express CD127, 
NKp46+ and NKp46- ILC1 and ILC3 populations did not express CD127. This was not 
entirely surprising as a recent study had shown that CD127 was not strictly required for 
the development of any ILC subsets231. These observations highlight the caveats of 
using conventional flow cytometry analysis that relies only on surface marker 
expression (i.e. Sca-1, CD127 or NKp46) to study ILCs under different conditions (i.e. 
vaccination or acute infection), especially given the high plasticity of ILC subsets 142, 209, 
218, 219, 228, 229, 230.  
 
Different ILC2 subsets arise from a common progenitor cell and under different 
cytokine conditions/ anatomical location differentiate into ILC2 that are IL-33R+, IL-
25R+ or TSLPR+232. Here we have for the first time demonstrated that route of 
vaccination can alter the ILC recruitment profile at the vaccination site. Following i.n. 
rFPV vaccination only ST2/IL-33R+ ILC2 (lung resident “natural” ILC) were detected 
in lung, while exclusively IL-25R+ ILC2s were detected in muscle following i.m. rFPV 
vaccination. IL-25R+ ILC2 in muscle were most likely circulatory “inflammatory” 
ILC2213 as naive muscle did not show any significant ILC2 subsets (Fig. 3.11). Both 
lung IL-33R+ ILC2s and muscle IL-25R+ ILC2s although expressed IL-13, did not 
express IL-4. As lineage+ cells did not express any IL-13 at 12 h or 24 h post 
vaccination, ILC2 were the only or major source of IL-13 at the vaccination site at these 
specific timepoints. Interestingly, a larger proportion of IL-13+ ILC2s were detected in 
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muscle following i.m. FPV-HIV vaccination compared to lung post i.n. delivery. These 
observations revealed that, what is observed at the ILC level could be directly translated 
into T cells level, where intramuscular poxviral vaccination has shown to induce 
elevated IL-13 expression by CTL responsible for low avidity T cells compared to 
mucosal delivery75. 
 
Moreover, IL-13Rα2 and IL-4R antagonist adjuvanted vaccines that induced high 
avidity CTL113, 122 showed significant inhibition of IL-13 expression by lung IL-33R+ 
ILC2 compared to control non-adjuvant vaccination. Taken together the ability of IL-13 
to modulate dendritic cell recruitment to the vaccination site 24 h post vaccination77, 
current findings clearly propose that level of IL-13 expressed by ILC2, could directly 
modulate dendritic cell recruitment to the vaccination site, responsible for the 
generation of uniquely different T cell immune outcomes (i.e. under low IL-13 
condition recruitment of CD11b+ CD103- conventional DC responsible for induction 
high avidity CTLs77). Interestingly, under allergic lung inflammation conditions IL-13 
but not IL-4 expressed by ILC2s have shown to promote migration of activated lung 
dendritic cells into the draining lymph nodes responsible for CD4+ T helper 2 cell 
activation197. Halim et al. have further demonstrated that IL-13+ ILC2 licence CD11b+ 
CD103- conventional DC to express CCL17 and promotes Th2 responses223, and our 
studies showed that blocking IL-13 activity likely inhibit this process and forces 
stronger Th1 mediated immunity123. In summary, these findings indicate that the ILC2 
bias (IL-25R+ or IL-33R+) observed at the different vaccination sites and the amount of 
IL-13 produced by these ILC2, play a critical role in defining the efficacy of a vaccine. 
This may also explain how and why mucosal vaccination (which induce low IL-13 
expression by ILC2) induce high avidity CTL with better protective efficacy against 
mucosal pathogens compared to systemic vaccination65, 73, 75. 
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IL-13 and IL-4 share a common receptor system comprised of IL-4Rα/IL-13Rα1, Type 
II IL-4 receptor complex233, 234, while IL-4 can also signal via Type I IL-4 receptor 
complex comprised of the common-γ chain and IL-4Rα235. Both these receptor 
complexes activate STAT6 signalling. IL-13Rα2 and IL-4R antagonist adjuvanted 
vaccines inhibited IL-13 expression by ILC2s compared to the control non-adjuvanted 
vaccine. Sequestering IL-13 (IL-13Rα2 adjuvanted vaccination) also reduced the overall 
percentage of ST2/IL-33R+ ILC2 suggesting an IL-13 autocrine role in maintaining 
ILC2 function. Surprisingly, sequestering IL-13 from the milieu verses blocking 
conventional IL-4Rα/IL-13Rα1/STAT6 signalling using IL-4R antagonist vaccines 
resulted in differing ILC1/ILC2 responses. These observations indicate that IL-13 
signalling via an alternative pathway, most likely IL-13Rα2 may possibly be 
responsible for the responses observed with the latter vaccination strategy. This can be 
further corroborated by the findings that under certain conditions, a physical interaction 
between cytoplasmic domains of IL-13Rα2 and IL-4Rα regulating IL-4Rα/IL-13Rα1 
receptor function236, and also IL-13 signalling via the not well defined high-affinity IL-
13Rα2 pathway has been reported237.  
 
Furthermore, IL-13Rα2 adjuvanted vaccination was associated with lower IFN-γ 
expression by both NKp46+/- ILC and conventional NK cell (Fig. 3.6) compared to the 
other two vaccines tested. Interestingly, a recent study has demonstrated that IL-1β, IL-
12 and IL-18 drive the plasticity between ILC2 and IFN-γ+ ILC1 populations238. Thus, 
the very low starting population of ILC2 induced under IL-13Rα2 adjuvanted vaccine 
may account for the reduced IFN-γ+ NKp46+/- ILC populations. However, whether this 
would directly affect the IFN-γ expression by conventional NK cell is not yet known 
(Fig. 3.6). In contrast, our study demonstrated that IFN-γ expression by lung NKp46- 
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ILC was elevated up to the day 7 experimental period, while IFN-γ expression by “ex-
ILC3” NKp46+ cells was largely unaffected following IL-4R antagonist adjuvant 
vaccination. It is accepted that IL-4/IL-13/STAT6 signalling is antagonistic to IFN-γ 
expression239. Thus, it is not entirely surprising that blocking the conventional IL-
4Rα/IL-13Rα1 pathway resulted in elevated IFN-γ expression by both NKp46- ILC and 
conventional NK cells. We have previously shown that vaccination using the IL-4R 
antagonist vaccine resulted in robust IgG1 and IgG2a antibody responses, whereas the 
IL-13Rα2 adjuvanted vaccine resulted in reduced IgG2a antibodies113. Interestingly, one 
major difference between the two adjuvanted vaccines were the level of IFN-γ 
expression by NKp46- ILC and NK cells suggesting this may ultimately influence APC 
activation and CD4+ T helper cells required for antibody isotype class switching. 
Blocking autocrine signalling via the IL-4R/IL-13Rα1 (blocking STAT6 signalling) 
may account for reduced ILC2 IL-13+ cell number, it has also been shown that ILC1 
IFN-γ expression can suppress IL-13 expression by tissue-resident natural ILC2 cells240. 
IFN-γ has shown to significantly inhibit IL-13 production by ILC2240, 241, 242, while also 
up-regulating extracellular expression of IL-13Rα2239. The above and our current 
findings indicate a complex interaction between IFN-γ and IL-13 signalling at the 
vaccination site, and the early IL-13 and IFN-γ co-dependency at the ILC level most 
likely playing an important role in shaping the downstream antibody immunity. 
 
Previous inflammation and asthma mouse models indicate NKp46- ILC1 express IFN-γ, 
NKp46- ILC3 express IL-17A and NKp46+ ILC3 express IL-22167, 168, 243. Interestingly, 
in this study, following intranasal viral vaccination both NKp46+ and NKp46- ILC1 and 
ILC3 were found to express IFN-γ and IL-22, but not IL-17A.  In contrast, following 
intramuscular vaccination NKp46+ ILC1 and ILC3 were found to express IFN-γ, IL-22 
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and IL-17A, while NKp46- ILCs only expressed IL-22 and IL-17A, not IFN-γ. These 
findings clearly indicate the ILC1/ILC3 and ILC2 populations induced are uniquely 
different depending upon the route of vaccination. Furthermore, the adjuvanted vaccine 
studies demonstrated that unlike i.n. delivery, the NKp46+ and NKp46- ILC1/ILC3 
subsets induced following i.m. vaccination have significantly different responsiveness 
to IL-13. For example: unadjuvanted and the IL-4R adjuvant vaccines showed 
significantly elevated IL-22 and IL-17A expression by NKp46- ILC1/ILC3 compared to 
IL-13Rα2 adjuvanted vaccine. Also, a larger proportion of IL-13+ ILC2s were detected 
following i.m. FPV-HIV vaccination compared to i.n. delivery. Taken together our 
previous studies on CD8+ T cells, where IL-13 has shown to modulate IL-17A 
activity226, we postulate that IL-17A expression in ILC1 and ILC3 is tightly regulated 
by IL-13-driven ILC2. In summary, these observations evoke the possibility that the 
NKp46+ or NKp46- ILC1 and ILC3 plasticity at vaccination site is co-dependent on the 
amount of IL-13 produced by different ILC2 subsets (IL-25R+ vs IL-33R+). 
 
Collectively, results indicate that within the first 24 h post-vaccination, according to the 
route of delivery and adjuvants used, different types of IL-13-driven ILC2 and IFN-γ 
/IL-17A/IL-22 expressing NKp46+ or NKp46- (ILC1 and ILC3) are recruited to the 
vaccination site. The IL-13 and IFN-γ/IL-17A balance induced by these ILCs, play a 
crucial role in shaping the resulting APC recruitment/activation and B and T cell 
immunity. Our data suggest that altering the functions of these different ILC subsets at 
the vaccination site, by regulating IL-13 signalling to induce the desired protective 
immune outcome needed according to the target pathogen (bacteria, viruses or parasites), 
may give rise to more efficacious vaccines in the future. 
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Chapter 4. 
Transient inhibition of IL-25 at the lung mucosae can 
significantly modulate ILC2 development and function.  
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4.1 Abstract. 
Intranasal immunisation with recombinant fowlpox viral vector-based vaccine co-
expressing an adjuvant that transiently sequesters IL-25 (FPV-HIV-IL-25BP) at the 
vaccination site was shown to induce ST2/IL-33R+, IL-25R+, and TSLPR+ ILC2 subsets 
in lung unlike unadjuvanted vaccine which only induced ST2/IL-33R+ ILC2. At 24 h 
post vaccination, all these lung ILC2 subsets expressed significantly different levels of 
IL-13, and the TSLPR+ ILC2 subset also expressed IL-4. Surprisingly, sequestration of 
IL-33 did not have any impact on lung ILC function, although the major ILC2 subset in 
lung following i.n. vaccination was ST2/IL-33R+ (Chapter 3), thus the current data 
suggest that during early lung ILC2 development cytokine IL-33 may not play an 
important role as IL-25. Interestingly, FPV-HIV-IL-25BP adjuvanted vaccination also 
induced elevated IL-17A and IFN-γ expression by ILC1/ILC3 in lung, suggesting that 
the level of ILC2-derived IL-13 in the milieu, can regulate ILC1/ILC3. Moreover, 
sequestration of IL-25 induced a uniquely different lineage- ST2/Il-33R- IL-25R- 
TSLPR- ILC2 population that expressed elevated IL-13 and IL-4. Taken together with 
previous findings, where elevated IL-4/IL-13 has been associated with induction of low 
avidity T cells following viral vector vaccination, current observations suggest that 
intranasal IL-25BP adjuvant delivery may promote the development of low avidity T 
cells. Collectively, these inhibitor studies indicate that IL-25 plays a more predominant 
role in early ILC development than IL-33, suggesting that IL-25 may be the master 
regulator of ILC at the lung mucosae. 
 
4.2 Introduction. 
The discovery of ILC2s began with the identification of a new subset of cells in RAG-
deficient mice (lacking B cells and T cells) that produced IL-5 and IL-13 in response to 
IL-25244. After a decade of research, in 2010, a group of type 2 cytokine-producing cells 
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which have the ability to produce IL-5 and IL-13 in response to IL-25 and IL-33 were 
identified and named as ILC2134, 135, 136. Later studies characterised these ILC2s into 
three different subsets (IL-33R/ST2+, IL-25R+, and TSLPR+) depending on their 
receptor expression in response to cytokines IL-33, IL-25, and TSLP135, 195, 245, 246, 247. 
Interestingly, large number of studies have now shown that IL-33, IL-25, and TSLP 
differentially modulate ILC2 activity. Specifically, in the context of tissue remodelling, 
allergy, and inflammation.134, 135, 144, 145, 149, 194, 248. 
 
Chapter 3, studies established that intranasal vaccination with rFPV induced IL-
33R/ST2+ ILC2 in the lung, whereas intramuscular rFPV vaccination induced IL-25R+ 
ILC2 in muscle. In naïve BALB/c lung only IL-33R/ST2+ ILC2 were detected, however 
neither IL-33R/ST2+ nor IL-25R+ ILC2 subsets were detected in naïve BALB/c muscle. 
These results indicated that IL-33R/ST2+ ILC2 are resident ILC in the lung mucosae, 
while IL-25R+ ILC2 are more likely ‘inflammatory’ ILC2 that migrate to muscle from 
blood213. The inflammatory ILC2 are characterized by their high expression of the 
maturation marker KLRG1 and the IL-25R but not IL-33R/ST2213. In addition, these 
inflammatory ILC2 have not only shown to play an important role in mediating anti-
helminth immunity, they also have shown to express RORγt and produce IL-17 in 
Candida albicans infection213 which has indicated that there is high plasticity between 
ILC2 and ILC3. Interestingly, the IL-33R/ST2- IL-25R+ inflammatory ILC2s have also 
shown to develop into IL-33R/ST2+ ILC2s both in vivo and in vitro under certain 
conditions213. Taken together these observations, we postulate that IL-25R+ ILC may be 
the precursor ILC that differentiate into ILC1, ILC2, and ILC3 under different 
stimulatory conditions. 
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Therefore, to further understand the role of IL-33 and IL-25 in ILC development 
specifically in the context of intranasal vaccination, in this study two novel rFPV 
vaccines were constructed to transiently inhibit IL-33 and IL-25 activity at the 
vaccination site, the lung mucosae. i) FPV-HIV-IL-33BP vaccine that co-expressed 
HIV antigen together with an IL-33 binding protein, that can sequester IL-33 
temporarily at the vaccination site, and ii) FPV-HIV-IL-25BP vaccine that co-expressed 
HIV antigen together with an IL-25 binding protein, that can sequester IL-25 
temporarily at the vaccination site (Fig 4.1). Knowing that IL-33R/ST2+ ILC2s were 
only detected in lung and IL-25R+ ILC2s were only observed in muscle following 
vaccination (Chapter 3), when WT BALB/c mice were intranasally vaccinated with 
FPV-HIV-IL-33BP, no differences in ILC recruitment or cytokine expression were 
observed in lung. However, when mice were vaccinated intramuscularly with FPV-
HIV-IL-25BP adjuvanted vaccine, significantly different ILC and cytokine profiles 
were detected (Jackson and Ranasinghe unpublished observations). These findings 
indicated that IL-25 most likely play a more important role in modulating ILC 
development and function than IL-33. Therefore, to understand this process further, 
specifically to establish how IL-25 cytokine impact development of lung and muscle 
ILC development, in this study, rFPV vaccine co-expressing the IL-25R (FPV-HIV-IL-
25RBP), was delivered intranasally and ILC and their cytokine expression profiles were 
evaluated 24 h post vaccination (This time point was chosen as in Chapter 3, data 
clearly established that ILC were significantly modulated at 24 h post viral vector 
vaccination). 
 
 
 
Fig. 4.1 IL-17 signaling pathway. 
The IL-17 family consists of six members IL-17A-F, while the IL-17 
receptor family consists of five members IL-17RA to IL-17RE. IL-
17RA is a common receptor that forms heterodimeric complexes 
with IL-17RB, IL-17RC, and IL-17RE. IL-17A and IL-17F signals 
through the IL-17RA-RC complex, triggering TRAF6-dependent 
target gene transcription. IL-17E (IL-25) signaling through the IL-
17RA-RB receptor complex induces Th2 responses by activating 
MAPK and NF-κB pathways. 
Adapted from Sino Biological
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4.3 Materials and Methods. 
4.3.1 Mice and immunisation. 
5-6 weeks old pathogen free female WT BALB/c mice were obtained from the 
Australian Phenomics Facility, the Australian National University, and were maintained 
and handled under protocols indicated in 2.2.1. 1×107 PFU unadjuvanted FPV-HIV, and 
FPV-HIV-IL-25BP adjuvanted vaccines prepared as per described in 2.2.3 and 2.2.4 
were administered to WT BALB/c mice (n = 6 per group) intranasally, under mild 
isoflurane anaesthesia as per described in 2.2.5. Lungs were harvested in 2 ml of 
complete RPMI 24 h post immunisation, and single cell suspension was prepared as per 
described in 2.2.6.  
 
4.3.2 Surface and intracellular staining. 
Surface and intracellular staining were performed as per described in 2.2.8, using 
antibodies details in Table 2.3. Specifically, 
ST2/IL-33R+ and IL-25R+ ILC2 staining: APC/Cy7-conjugated anti-mouse CD45, 
and FITC-conjugated lineage cocktail were used to identify the lineage- cells. PE-
conjugated anti-mouse ST2/IL-33R, and APC-conjugated anti-mouse IL-25R were used 
to identify the different ILC2 subsets. Brilliant Violet 421-conjugated anti-mouse IL-4 
and PE-eFlour 610-conjugated anti-mouse IL-13 were used to evaluate intracellular 
expression of theses cytokines in ILC2. The gating strategy indicated in Fig. 2.3 was 
used to identify the different ILC2 subsets and their cytokine expression. 
 
ST2/IL-33R+ & TSLPR+ ILC2 staining: APC/Cy7-conjugated anti-mouse CD45, and 
FITC-conjugated lineage cocktail were used to identify the lineage- cells as per before. 
PerCP/Cy5.5-conjugated anti-mouse ST2/IL-33R, and APC-conjugated anti-mouse 
TSLPR were used to identify different ILC2 subsets. (In this staining cocktail, since the 
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TSLPR antibody was found to interact with PE-conjugated anti-mouse ST2/IL-33R 
antibody, PerCP/Cy5.5-conjugated anti-mouse ST2/IL-33R was used). To avoid 
spectral overlap, Brilliant Violet 421-conjugated anti-mouse IL-4 and PE-conjugated 
anti-mouse IL-13 were used to evaluate the intracellular cytokine expression in ILC2. 
 
ILC1 and ILC3 staining: APC/Cy7-conjugated anti-mouse CD45, and FITC-
conjugated lineage cocktail were used to identify lineage- cells. PE-conjugated anti-
mouse ST2/IL-33R, and Brilliant Violet 421-conjugated anti-mouse CD335 (NKp46) 
were used to identify the ILC1 and ILC3 populations. Brilliant Violet 510-conjugated 
anti-mouse IFN-γ, APC-conjugated anti-mouse IL-22, and Alexa Fluor 700-conjugated 
anti-mouse IL-17A were used to evaluate the intracellular cytokine expression in ILC1 
and ILC3 subsets.  
 
Staining strategy of the novel ST2/IL-33R- IL-25R- TSLPR- ILC2 subset:  
1x106 lung cells were stained in four different wells using range of fluorochromes as per 
indicated in the flow chat 4.1. Specifically, IL-25R and TSLPR were stained separately 
to avoid spectral overlap using PE-conjugated ST2/IL-33R and PerCP/Cy5.5-
conjugated ST2/IL-33R respectively. (In this staining cocktail, as the TSLPR antibody 
was found to interact with PE-conjugated anti-mouse ST2/IL-33R antibody, 
PerCP/Cy5.5-conjugated anti-mouse ST2/IL-33R was used). IL-13 and IL-4 expression 
in all known ILC2 subsets (ST2/IL-33R+, IL-25R+, and TSLPR+), including the lineage- 
ST2/IL-33R- IL-25R- TSLPR- population were evaluated. NKp46, IFN-γ, and IL-17A 
were also stained to established that ILC1 and ILC3 cells did not express IL-4 or IL-13  
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Flowchart 4.1: ST2/IL-33R- IL-25R- TSLPR- ILC2 staining strategy. 
 
 
4.4 Results. 
4.4.1 Following i.n. FPV-IL-25BP vaccination lineage- IL-33R/ST2- IL-
25R+ and lineage- IL-33R/ST2- TSLPR+ ILC2 subsets were recruited to 
the lung mucosae. 
WT BALB/c mice were vaccinated intranasally with the unadjuvanted FPV-HIV 
vaccine or the FPV-HIV IL-25BP adjuvanted vaccine (which sequestered IL-25 at the 
vaccination site). As ILC subsets were shown to be manipulated mainly at 24 h post 
vaccination (Chapter 3), in this study, different ILC subsets and their cytokines 
expression were evaluated only at 24 h post vaccination. Data indicated that while the 
unadjuvanted vaccine only induced lineage- IL-33R/ST2+ ILC2 in lung (Fig. 4.2a), the 
FPV IL-25BP adjuvanted vaccine not only induced lineage- IL-33R/ST2+ ILC2s but 
also induced lineage- IL-33R/ST2- IL-25R+ and lineage- IL-33R/ST2- TSLPR+ ILC2 
subsets in the lung mucosae (Fig. 4.2a). Although no significant differences in the 
lineage- IL-33R/ST2+ ILC2 cell numbers were observed between unadjuvanted control 
and IL-25BP adjuvanted vaccination (Fig. 4.2b), significantly elevated numbers of 
lineage- IL-33R/ST2- IL-25R+ ILC2 (p=0.0004) (Fig. 4.2c) and  
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lineage- IL-33R/ST2- TSLPR+ ILC2 (p<0.0001) (Fig. 4.2d) were observed in FPV-IL-
25BP vaccinated group compared to the unadjuvanted control. 
 
4.4.2 Following FPV-IL-25BP vaccination distinctive IL-13 and IL-4 
expression profiles were detected in the different lung ILC2 subsets. 
Next when IL-13 expression in ILC2 subsets was evaluated, post intranasal FPV-HIV-
IL-25BP vaccination, all three ILC2 subsets (IL-33R/ST2+ ILC2, IL-25R+ ILC2 and 
TSLPR+ ILC2) were shown to express IL-13 (Fig. 4.3a). Specifically, compared to the 
unadjuvanted vaccine group, FPV-HIV-IL-25BP adjuvanted group showed significantly 
reduced IL-13 expression by IL-33R/ST2+ ILC2s (p<0.0001) (Fig. 4.3b), In contrast, 
IL-13 expression in IL-33R/ST2- IL-25R+ and IL-33R/ST2- TSLPR+ ILC2 subsets 
(which were not observed following unadjuvanted vaccination) were significantly 
elevated (Fig. 4.3b). Interestingly, in mice given FPV-HIV-IL-25BP vaccination, IL-
33R/ST2- TSLPR+ ILC2s showed significantly elevated IL-13 expression compare to 
IL-33R/ST2+ ILC2 subset (p = 0.0126) (Fig. 4.3b).  
 
All vaccines tested in Chapter 3 (specifically vaccine that transient inhibited IL-4/IL-13) 
did not show any IL-4 expression by IL-33R/ST2+ ILC2s. However interestingly, 
following intranasal FPV-HIV-IL-25BP adjuvanted vaccination, elevated IL-4 
expression was detected in lineage- IL-33R/ST2- TSLPR+ ILC2, but not the other two 
ILC2 subsets (Fig. 4.3c & d). The IL-33R/ST2- TSLPR+ ILC2 subset that expressed IL-
13 were not positive for IL-4 (Fig. 4.3c).  
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4.4.3 Following FPV-HIV-IL-25BP vaccination lineage- IL-33R/ST2- 
NKp46+/- ILCs were found to express IFN-γ and IL-17A. 
When lineage- IL-33R/ST2- NKp46+ ILCs in lung were assessed 24 h post intranasal 
FPV-HIV-IL-25BP adjuvanted vaccination, significantly elevated numbers of lineage- 
IL-33R/ST2- NKp46+ ILCs were observed compared to the unadjuvanted vaccine (Fig. 
4.4a). The lineage- IL-33R/ST2- NKp46+ ILCs obtained from the IL-25BP adjuvanted 
vaccinated group expressed elevated IFN-γ compared to unadjuvanted vaccine group, 
p<0.0001) (Fig. 4.4b), and more interestingly, were also found to express elevated IL-
17A (Fig. 4.4c). Unlike IFN-γ and IL-17A, in the context of IL-22 expression, FPV-
HIV-IL-25BP adjuvanted vaccine showed significantly reduced IL-22 expression by 
lineage- IL-33R/ST2- NKp46+ ILC compared to the unadjuvanted vaccine (p<0.001) 
(Fig. 4.4d).  
 
Next when the lineage- IL-33R/ST2- NKp46- ILCs were assessed following intranasal 
FPV-HIV-IL-25BP vaccination, most of the lineage- IL-33R/ST2- cells were found to be 
NKp46- (Fig. 4.5a). However, unlike the lineage- IL-33R/ST2- NKp46+ cells, there were 
no significant differences in the lineage- IL-33R/ST2- NKp46- ILCs cell numbers (Fig. 
4.5a) and their IFN-γ expression between the adjuvanted and unadjuvanted groups (Fig. 
4.5b). Interestingly, similar to the lineage- IL-33R/ST2- NKp46+ cells, elevated IL-17A 
expression was detected in the lineage- IL-33R/ST2- NKp46- ILCs following FPV-HIV-
IL-25BP vaccination (Fig. 4.5c). In contrast, significantly reduced IL-22 expression 
(p<0.0001) was detected in lineage- IL-33R/ST2- NKp46- ILCs (Fig. 4.5d).  
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4.4.5 Following intranasal FPV-HIV-IL-25BP vaccination a novel 
lineage- IL-33R/ST2- IL-25R- TSLPR- ILC2 cell subset expressing IL-
13 and IL-4 was discovered. 
FPV-HIV-IL-25BP adjuvanted vaccination induced all three known ILC2 subsets 
(lineage- IL-33R/ST2+, lineage- IL-33R/ST2- IL-25R+ and lineage- IL-33R/ST2- 
TSLPR+), and they were found to express IL-13 and the TSLPR+ subset also expressed 
IL-4. As expected, these ILC2 subsets did not express IL-17A or IFN-γ (Fig. 4.6a-c). 
Surprisingly, in the lineage- IL-25R- IL-33R/ST2- TSLPR- cell population, group of cells 
were found not only to express IL-13 but also IL-4. In this subset, the IL-4/IL-13 
expression was much greater than the other three ILC2 subsets (p<0.0001) (Fig. 4.6d-f). 
A small subset was also found to be double positive for both IL-13 and IL-4 (Fig. 4.6d). 
These observations suggested that lineage- IL-25R- IL-33R/ST2- TSLPR- population 
could contain a not yet defined ILC2 subset. In this analysis the lineage- IL-33R/ST2- 
TSLPR- NKp46+ and NKp46- cells that produced IL-17A and IFN-γ were most likely 
classic ILC1 and ILC3, not ILC2 as none of the known ILC2s express these two 
cytokines (Fig. 4.6d). 
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4.5 Discussion. 
Following intranasal FPV-HIV-IL-25BP vaccination, where IL-25 was temporarily 
sequestered from the vaccination site, significant impact on ILC development/function 
in lung mucosae were observed, similar to that of muscle following intramuscular 
vaccination. Specifically, in relation to lung ILC2, not only ST2/IL-33+ ILC2, but also 
IL-25R+, TSLPR+ ILC2 and also a unique lineage- IL-33R/ST2- IL-25R- TSLPR- ILC2 
subsets that expressed IL-13 or IL-4 were detected 24 h post vaccination, unlike mice 
given the unadjuvanted FPV-HIV vaccination. Interestingly, knowing that sequestration 
of IL-33 (FPV-HIV-IL-33BP adjuvanted vaccine) had no impact on ILC2 
development/function in lung, although the major ILC2 subset in lung following i.n. 
vaccination was ST2/IL-33R+ (Chapter 3), these unexpected finding suggested a 
hierarchical role of IL-25 in ILC2 development compared to IL-33. 
 
Different ILC2 subsets arise from a common progenitor cell and under different 
cytokine conditions/anatomical location differentiate into ILC2 that are IL-33R+, IL-
25R+ or TSLPR+232, 249. Chapter 3 studies have shown that in naïve mice, IL-33R/ST2+ 
ILC2 are the resident ILC population in lung, while IL-25R+ ILC2 (which are known as 
the “inflammatory” ILC213) were recruited to the muscle only following i.m. vaccination. 
Current study demonstrated that transient inhibition of IL-25 at the vaccination site can 
promote some ILC2s at the lung mucosae to express both IL-13 as well as IL-4. 
Interestingly, the IL-4 expressing ILC2s induced by FPV-HIV-IL-25BP adjuvanted 
vaccination did not express IL-13, suggesting that these were two distinct ILC2 
populations. Recent studies have also shown that addition of IL-25 and IL-33 can 
promote differential cytokine expression by lung IL-33R/ST2+ ILC2. For example, 
when lung IL-33R/ST2+ ILC2 were cultured in the presence of IL-25 in vitro, these 
cells were shown to produce elevated IL-13 but reduced IL-5 whereas the inverse was 
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reported when cells were cultured in the presence of IL-33250, 251. Furthermore, Chen et 
al using IL-13-GFP reporter mice have also shown that compared to IL-33, intranasal 
administration of recombinant IL-25 can induce elevated IL-13 expression by lung 
ILC2250. Interestingly, the current study demonstrated that removal of IL-25 from the 
cell milieu can have a much profound impact on ILC2 differentiation (induction of 
range of ILC2 subsets) including IL-13/IL-4 expression by these ILC2s, unlike 
overexpression of IL-25. These observations further support the notion that IL-25 may 
play a more important role in ILC2 development in lung than IL-33. 
 
Our previous studies have shown that mucosal vaccination induced high avidity CD8+ T 
cells and this was associated with low level of IL-13 expressed by T cells77. In contrast, 
systemic vaccination induced low avidity CD8+ T cells associated with elevated level of 
IL-1377. Transient inhibition of IL-4 and IL-13 at the vaccination site has shown to 
induce i) T cells of high avidity and ii) unlike IL-13Rα2 adjuvanted vaccination IL-4R 
antagonist vaccination has also shown to induce excellent antibody differentiation113, 122, 
suggesting IL-13 plays an important role in modulating both T and B cell immunity78, 79. 
These studies also showed that level of IL-4/IL-13 at the vaccination site can 
significantly alter the activity of antigen presenting cells123. When trying to dissect 
which cells at the vaccination site produced IL-13, Chapter 3 studies have clearly 
established that ILC2 are the major source of IL-13 at the vaccination site 24 h post 
viral vector vaccination. Interestingly, low IL-4/IL-13 levels were associated with 
recruitment of CD11b+ CD103- conventional DCs, and induction of high avidity HIV-
specific CD8+ T cells123. Intranasal FPV-HIV-IL-25BP adjuvanted vaccination was 
shown to induce significantly elevated level of both IL-4 and IL-13 by ILC2 at the lung 
mucosae 24 h post vaccination. Taken together our previous findings and the elevated 
IL-13 observed following intranasal FPV-HIV-IL-25BP adjuvanted vaccination, data 
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suggest that sequestration of IL-25 at the lung mucosae may be detrimental for the 
induction of high avidity T cells. However, intramuscular FPV-HIV-IL-25BP 
vaccination significantly inhibited both IL-4 and IL-13 expression by ILC2 in muscle 
(Jackson and Ranasinghe unpublished data), suggesting that IL-25BP could be a highly 
efficacious intramuscular but not an intranasal adjuvant. 
 
Interestingly, FPV-HIV-IL-25BP adjuvanted vaccination not only manipulated the ILC2 
differentiation/function but also ILC1 and ILC3 at the vaccination site. This was highly 
unexpected as cytokine IL-25 was thought to be an activator of ILC2 but not 
ILC1/ILC3249. Surprisingly, compared to the unadjuvanted rFPV vaccination, transient 
removal of IL-25 at the lung mucosae was induced elevated expression of IL-17A by 
lineage- IL-33R/ST2-NKp46+/- ILC1 and ILC3. Ravichandran et al. have previously 
demonstrated that IL-4 and IL-13 can differentially regulate IL-17A in antigen-specific 
CD8+ T cells226. As FPV-HIV-IL-25BP vaccination also significantly manipulated IL-4 
and IL-13 expression by the different ILC2 subsets (IL-33R/ST2+, IL-25R+, TSLPR+, 
and the unique lineage- IL-33R/ST2- IL-25R- TSLPR- ILC2 subsets), we postulate that 
the significant changes in IL-17A production in ILC1/ILC3 could be associated with the 
high level of IL-4/IL-13 expressed by the different ILC2 subsets, including the novel 
lineage- IL-33R/ST2- IL-25R- TSLPR- ILC2 subset. Moreover, IL-25 (IL-17E), signals 
via the IL-25 receptor complex IL-17RA/IL-17RB, and IL-17RA/ IL-17RC is the major 
receptor complex for IL-17A signaling252, 253(Fig. 4.1). Therefore, following IL-25BP 
vaccination the elevated IL-17A expressed by ILC1/ILC3 could also be associated with 
the balance of IL-17A and IL-25 signalling. For example; sequestration of IL-25 
initiating the IL-17A signalling via NF-κB, Activator Protein 1 (AP-1) and CCAAT-
enhancer-binding-protein (C/EBP) pathways (Fig 4.1). This could be similar to what 
has been observed during transient inhibition of IL-13, in which IL-4 signalling via the 
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STAT6 pathway was initiated113, 122(Chapter 3). The level of IL-13 expressed by ILC2 
was also shown to alter the expression of IFN-γ by ILC1 and ILC3 (Chapter 3). 
Specifically, transient blockage of IL-4/IL-13 signalling via STAT6 pathway, compared 
to transient inhibition of IL-13 at the vaccination site differentially regulated IL-13 
expression by ILC2 and IFN-γ expression by ILC1/ILC3. These findings support the 
notion that in the context of viral vector vaccination, IL-13 produced by ILC2 could be 
the master regulator of ILC1 and ILC3 activity, specifically the IFN-γ, IL-17 and also 
IL-22 expression by these cells 24 h post vaccination. 
 
This study clearly established that manipulating IL-25 at the lung mucosae can have not 
only dramatic impact on ILC2 and their IL-13/IL-4 expression, but also have significant 
effects on ILC1/ILC3 cells and their IFN-γ/IL-22/IL-17A production. Several studies, 
including ours have shown that IL-25 and IL-33 may have different impacts on ILC 
development and function147, 194, 254. Stier et al. have shown that IL-33 plays a crucial 
role in promoting ILC2 egress from the bone marrow255. Hence, we propose that IL-33 
may be critical for ILC homing and trafficking to tissue255, whereas IL-25 may be 
important for initial ILC development and function. Following IL-25 sequestration, the 
lineage- IL-33R/ST2- IL-25R- TSLPR- ILC2 population observed, could be an 
undifferentiated ILC2 subset (i.e. similar to CD4- CD8- T cell development) or a not yet 
defined ILC2 subset. However, in context given the expression of IL-4 and IL-13 by 
these cells, the latter explanation appears to be may be more valid. In conclusion, 
current findings further substantiate that the adjuvants used and the route of delivery 
play an important role in modulating ILC-driven cytokine expression at the vaccinations 
site, and these early events need to be seriously taken into consideration when designing 
effective vaccines against chronic pathogens. Following IL-25 sequestration, as 
TSLPR+ ILC2 were found to express IL-4 and IL-13, it would also be of interest to 
142 
 
study the impact of inhibition or sequestration TSLP at the vaccination site, and this 
warrants further investigation. 
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Chapter 5. 
Evaluation of ILC subsets in IL-4, IL-13 and STAT6 
knockout mice following intranasal rFPV vaccination. 
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5.1 Abstract. 
This study demonstrated that ILC and their cytokine expression profiles (IL-13, IFN-γ 
and IL-22) were vastly different during permanent (gene knockout) verses transient 
blockage of IL-13, IL-4, and STAT6 at the vaccination site. STAT6-/- mice given the 
FPV-HIV vaccine showed elevated ST2/IL-33R+ ILC2-driven IL-13 expression whilst 
reduced IFN-γ expression by both NKp46+/- ILC1/ILC3 24 h post intranasal vaccination. 
In contrast, when STAT6 signalling was transiently blocked in BALB/c mice using 
FPV-HIV-IL-4R antagonist vaccination, the opposing effect was observed, eliciting 
high IFN-γ expression. When IL-13-/- mice were vaccinated with FPV-HIV significantly 
elevated lung lineage- ST2/IL-33R+ ILC2s were detected compared to BALB/c mice 
given the FPV-HIV-IL-13Rα2 adjuvanted vaccine (transient inhibition of IL-13), and 
their NKp46+/- ILC1/ILC3-driven IFN-γ expression was significantly lower compared to 
transient inhibition of STAT6. In previous studies when IL-13 was inhibited, no or low 
HIV gag specific IgG1 and IgG2a antibody differentiation has been reported, unlike 
STAT6 inhibition. Thus, current data further corroborate that ST2/IL-33R+ ILC2-
derived IL-13 plays a crucial role in modulating downstream B cell immune outcomes. 
Specifically, co-regulation of ST2/IL-33R+ ILC2-derived IL-13 and NKp46+/- 
ILC1/ILC3-derived IFN-γ may play an important role in modulating IgG1 to IgG2a 
antibody differentiation process in a STAT6 independent manner via the IL-13Rα2 
pathway.  
 
5.2 Introduction. 
Cytokines IL-13 and IL-4 have been well studied in models which are related to Th2 
immunity such as allergy, asthma, parasitic and helminth infections80, 81, 82, 256, 257. The 
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roles of these two cytokines have been characterised as the regulators of Th1 and Th2 
immune responses80, 81, 258.  
The two poxviral vector based HIV vaccines, IL-13Rα2 adjuvanted and IL-4R 
antagonist adjuvanted vaccines described in Chapter 3, that can temporarily manipulate 
IL-13 and IL-4 activity at the vaccination site, have shown to induce higher 
avidity/multi-functional HIV specific effector/memory CD8 T cells with improved CD8 
T cell mediated protective efficacy122. Moreover, in the context of antibody immunity, 
the FPV-HIV-IL-4R antagonist adjuvant vaccine has also shown to induce HIV gag-
specific IgG1 and IgG2a antibody differentiation, but not the FPV-HIV-IL-13Rα2 
adjuvanted vaccine113. To further understand the role of IL-13 in IgG1/IgG2a antibody 
differentiation, IL-13-/-, IL-4-/-, and STAT6-/- mice were vaccinated with FPV-HIV/VV-
HIV (unadjuvanted) prime-boost strategy. Although IL-4-/- and STAT6-/- animals 
showed enhanced IgG2a antibody responses, IL-13-/- showed very low IgG2a antibodies 
(Hamid et al EJI accepted). More interestingly, when STAT6-/- mice were given the 
FPV-HIV-IL-13Rα2 adjuvanted vaccine, which sequestered IL-13 at the vaccination 
site, elevated IgG1 but low IgG2a antibody responses were detected similar to the IL-
13-/- mice (Hamid et al EJI accepted). These observations clearly indicated that i) unlike 
T cell immunity, presence of IL-13 was critical for B cell differentiation, and ii) taken 
together the STAT6-/- and IL-4R antagonist data indicated that signalling via IL-13Rα2 
pathway may be involved in this process (Hamid et al EJI accepted). Knowing that IFN-
γ plays an important role in antibody differentiation259, 260, 261, 262, 263, and chapter 3 
showing that ILC2 are the major source of IL-13 at the vaccination site and IL-13Rα2 
adjuvanted vaccine and IL-4R antagonist vaccines, differentially regulated IFN-γ at the 
vaccination site, we postulate that balance between ILC2-driven IL-13 and ILC1/ILC3-
driven IFN-γ at the vaccination site most likely play a critical role in shaping the 
downstream B cell immune responses.  
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IL-13 and IFN-γ have shown to regulate each other under different conditions264, 265, 266, 
267, 268. Under inflammation condition, IFN-γ has shown to inhibit ILC2 aviation and IL-
5 production269, however, the relationship between IL-13 and IFN-γ at the ILC level 
under viral vector vaccination is still poorly understood. Thus, in this study we have 
used IL-13, IL-4, and STAT6 gene knockout mice (permanent verses transient blockage 
-Chapter 3) to further understand the roles of these different ILC subsets following 
rFPV viral vector vaccination and to gain better understanding of how the balance of 
ILC2-driven IL-13 and ILC1/3-driven IFN-γ at the vaccination site modulate B cell 
activation.  
 
5.3 Materials and Methods. 
5.3.1 Mice and immunisation. 
5-6 weeks old pathogen free female WT BALB/c, IL-13-/-, IL-4-/-, STAT6-/- mice were 
obtained from the Australian Phenomics Facility, the Australian National University, 
and were maintained and handled under protocols indicated in 2.2.1. 1×107 PFU 
unadjuvanted FPV-HIV vaccine was administered to each mice group (n = 3 - 6 per 
group) intranasally under mild isoflurane anaesthesia as per described in 2.2.5. Lungs 
were harvested in 2 ml of complete RPMI at 24 h, 3 and 7 days post immunisation, 
single cell lung suspensions were prepared, stained and analysed as per described in 
2.2.6 and 2.2.8.  
 
5.3.2 Surface and intracellular staining. 
Surface and intracellular staining were performed as per described in 2.2.8 using 
antibodies listed in Table 2.3. Specifically, 
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ILC2 staining: APC/Cy7-conjugated anti-mouse CD45, and FITC-conjugated lineage 
cocktail were used to identify lineage- cells. PE-conjugated anti-mouse ST2/IL-33R, 
APC-conjugated anti-mouse Sca-1 were used to identify the ILC2. Brilliant Violet 421-
conjugated anti-mouse IL-4 and PE-eFlour 610-conjugated anti-mouse IL-13 were used 
to evaluate intracellular expression of these cytokines in ILC2s. 
 
ILC1/3 staining: APC/Cy7-conjugated anti-mouse CD45, and FITC-conjugated lineage 
cocktail were used to identify lineage- cells. PE-conjugated anti-mouse ST2/IL-33R, 
and Brilliant Violet 421-conjugated anti-mouse CD335 (NKp46) were used to identify 
ILC1/3 populations. Brilliant Violet 510-conjugated anti-mouse IFN-γ, APC-conjugated 
anti-mouse IL-22, and Alexa Fluor 700-conjugated anti-mouse IL-17A were used to 
evaluate intracellular expression of these ILC1/3 cytokines in ILC1 and ILC3.  
 
All ILC subsets were gated and analysed as per described in 2.2.9. 
 
5.4 Results. 
5.4.1 Following i.n. rFPV vaccination lung lineage- IL-33R/ST2+ ILC2 
in IL-4-/-, IL-13-/- and STAT6-/- mice were significantly different 
compared to WT BALB/c mice.  
In this study, WT BALB/c, IL-13-/-, IL-4-/-, and STAT6-/- mice (each group n = 3 - 6) 
were vaccinated intranasally with the unadjuvanted FPV-HIV vaccine and lung lineage- 
IL-33R/ST2+ ILC2 were evaluated 24 h, 3 and 7 days post vaccination, using 
multicolour flow cytometry as described in Materials and Methods. Data revealed that 
compared to WT BALB/c mice, all knockout animals showed significantly elevated 
lung lineage- IL-33R/ST2+ ILC2 24 h post vaccination (WT BALB/c vs IL-13-/-, 
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p<0.0001; WT BALB/c vs IL-4-/-, p=0.0013; WT BALB/c vs STAT6-/- p<0.0001). 
However, interestingly, at day 3 post vaccination, lineage- IL-33R/ST2+ ILC2 numbers 
in lung decreased significantly in knockout mice compared to the control WT BALB/c 
(Fig. 5.1a & 1b). Consistent with what was observed in the previous chapter, at 7 days 
post vaccination very low numbers of lung lineage- IL-33R/ST2+ ILC2 were detected in 
all groups tested.  
 
Unlike transient inhibition of IL-13 at the vaccination site with IL-13Rα2 adjuvanted 
vaccine described in Chapter 3, IL-13-/- mice showed significantly elevated numbers of 
lung lineage- IL-33R/ST2+ ILC2 24 h post vaccination (p<0.0001) (Fig 5.1c). Similarly, 
STAT6-/- mice (where no IL-13 and IL-4 signalling occur via STAT6 pathway), showed 
significantly higher lung lineage- IL-33R/ST2+ ILC2 24 h post vaccination compared to 
IL-4 -/-, IL-13-/- and WT BALB/c mice (Fig. 5.1b). Interestingly, out of the three 
knockout mice groups tested the lowest number of lung lineage- IL-33R/ST2+ ILC2s 
were detected in IL-4-/- 24 h post vaccination.  
 
5.4.2 In KO mice the Sca-1 regulation on lung lineage- IL-33R/ST2+ 
ILC2 was mainly observed at 24 h post vaccination.  
Next when stem cell marker Sca-1 expression was evaluated on lineage- IL-33R/ST2+ 
ILC2, unlike WT BALB/c mice where an increase in Sca-1+ ILC were detected over 
time, in gene knock-out mice differences in Sca-1+ ILC were only observed at 24 h post 
vaccination (Fig. 5.2a). Furthermore, compared to the other two knockout mice groups, 
relatively low Sca-1 expression was detected in IL-4-/- lineage- IL-33R/ST2+ ILC2 (Fig. 
5.2b). In contrast, elevated numbers of Sca-1+ lineage- IL-33R/ST2+ ILC2 were detected 
in both IL-13-/- mice and STAT6-/- mice at 24 h post vaccination (Fig. 5.2b & c). In 
general, the trend of Sca-1 expression 24 h to 7 days post immunisation was  
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significantly different in IL-13, IL-4 and STAT6 gene knock-out mice compared to the 
WT control BALB/c mice. 
 
5.4.3 WT BALB/c and STAT6-/- mice showed elevated numbers of lung 
lineage- IL-33R/ST2+ ILC2 expressing IL-13 compared to IL-4-/- mice. 
Next when IL-13 expression was evaluated in lung lineage- IL-33R/ST2+ ILC2, all time 
points tested significantly lower IL-13 levels were detected in IL-4-/- mice compared to 
WT BALB/c and STAT6-/- mice (Fig. 5.3a & b). Although the IL-13 expression in 
STAT6-/- lineage- IL-33R/ST2+ lung ILC2 was significantly higher than WT BALB/c at 
24 h post vaccination (Fig. 5.3a & b), no IL-13 expression was detected 3 days post 
vaccination (Fig. 5.3b). Moreover, no IL-4 expression was detected in any of the lung 
lineage- IL-33R/ST2+ ILC2 obtained from knockout mice or WT control BALB/c, 
including IL-13-/- mice.  
 
5.4.4 Lung lineage- IL-33R/ST2- NKp46+/- ILC1/ILC3 numbers were 
regulated differently in IL-13-/-, IL-4-/-, and STAT6-/- mice. 
When lineage- IL-33R/ST2- NKp46+ lung ILC (ILC1 /ILC3) were assessed following 
i.n. rFPV vaccination in gene knockout mice, significantly reduced numbers were 
observed compared to WT BALB/c mice (Fig. 5.4a). This reduction was more 
pronounced 3 to 7 days post vaccination (Fig. 5.4b). Although there was no significant 
difference in the lung lineage- IL-33R/ST2- NKp46+ ILC numbers in all three KO mice 
groups at day 3 post vaccination, at 24 h, these ILC numbers were significantly elevated 
in the IL-4-/- group, compared to IL-13-/- group these (Fig. 5.4b). Moreover, 7 days post 
vaccination, lung lineage- IL-33R/ST2- NKp46+ ILC numbers in STAT6-/- mice were 
slightly elevated compared to IL-4-/- mice (Fig. 5.4b). 
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Unlike lung lineage- IL-33R/ST2- NKp46+ ILCs, when lung lineage- IL-33R/ST2- 
NKp46- ILC in KO mice were assessed, significant differences were observed between  
the four mice groups at all time points tested (Fig. 5.4c). Specifically, whilst lineage- 
IL-33R/ST2- NKp46- ILC numbers in WT BALB/c mice and IL-13-/- mice showed 
similar trends overtime, IL-4-/- mice showed no significant changes at 24 h, 3 and 7 days 
post intranasal vaccination (Fig. 5.4d). Compared to all KO mice tested, IL-4-/- mice 
showed the lowest number of NKp46- ILC at 24 h post vaccination. Interestingly, 
elevated numbers of lineage- IL-33R/ST2- NKp46- ILC were detected in IL-13-/- mice 
and STAT6-/- compared to both control WT BALB/c and IL-4-/- mice at 24h post 
vaccination (Fig. 5.4d). However, the STAT6-/- mice showed significantly reduced 
NKp46- ILC at 3 and 7 days post vaccination compared to both WT BALB/c and IL-13-
/- mice. The profiles at 3 and 7 days post vaccination in IL-4-/- mice were similar to 
STAT6-/- mice (Fig. 5.4d).  
 
5.4.5 Following intranasal vaccination, STAT6-/- mice showed 
extremely low lung lineage- IL-33R/ST2- NKp46+/- ILC1/ILC3 
expressing IFN-γ and IL-22.  
Although IFN-γ and IL-22 expression in lung lineage- IL-33R/ST2- NKp46+ ILC were 
significantly lower in KO mice compared to WT BALB/c mice, STAT6-/- mice showed 
the lowest expression of both cytokines at all time points tested (Fig. 5.5a - d). The low 
IFN-γ and IL-22 expression by lineage- IL-33R/ST2- NKp46+ ILC at 3 to 7 days post 
vaccination (Fig. 5.5b & d), was reflective of the overall low numbers of lineage- IL-
33R/ST2- NKp46+ ILC in KO mice at these time points (Fig. 5.4). Unlike IFN-γ, in the 
context of IL-22 expression, IL-4-/- mice shows much elevated levels compared to IL-
13-/- (Fig. 5.5d). In all groups tested, none of the NKp46+ ILC were found to express IL-
17A.  
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When IFN-γ, IL-22 and IL-17A cytokines expression was evaluated in lineage- IL-
33R/ST2- NKp46- ILC, extremely low IFN-γ expression was detected in STAT6-/- mice 
at all time points tested (Fig. 5.6a & b). In IL-13-/- mice, although significantly reduced 
IFN-γ expression was detected at 24 h post vaccination (Fig. 5.6a & b), elevated levels 
were detected after 3 days post vaccination (Fig. 5.6b). No significant difference in 
IFN-γ expression by lineage- IL-33R/ST2- NKp46- ILC were detected in IL-4-/- mice 
and WT BALB/c mice at 24 h post vaccination (Fig. 5.6a & b), and rapid reduction in 
IFN-γ expression was observed 3 days post vaccination, unlike IL-13-/- mice (Fig. 5.6b). 
In the context of IL-22 expression by lineage- IL-33R/ST2- NKp46- ILC, IL-13-/- mice 
and STAT6-/- mice showed significantly reduced IL-22 expression at all time points 
tested (Fig. 5.6c & d). IL-4-/- mice showed significantly elevated level of IL-22 
expression by NKp46- ILC compared to IL-13-/- and STAT6-/- mice at 24 h post 
vaccination (Fig. 5.6d). Similar to lineage- IL-33R/ST2- NKp46+ ILC, none of the 
lineage- IL-33R/ST2- NKp46- ILC were found to express IL-17A. 
 
5.4.6 Following viral vector vaccination, ILC2-driven IL-13 and 
ILC1/ILC3-driven IFN-γ expression were inversely correlated.  
Next, the IL-13 expression profile of lung IL-33R/ST2+ ILC2, and IFN-γ expression by 
both NKp46+/- ILC1/ILC3 obtained from BALB/c mice given the FPV-HIV-IL-4R 
antagonist and IL-13-/-, FPV-HIV-IL-13Rα2 adjuvanted vaccines were compared with 
IL-13-/-, STAT6-/-, and IL-4-/- mice given the control unadjuvanted vaccine (Fig. 5.7a). 
STAT6-/- and IL-4-/- mice showed elevated IL-13 expression by ILC2 compared to the 
BALB/c mice given the adjuvanted vaccines (Fig. 5.7a). However, ILC2-driven IL-13 
expression was significantly higher in STAT6-/- mice compared to IL-4-/- mice (Fig. 
5.7a). When IFN-γ expression by both NKp46+/- ILC1/ILC3 were evaluated, the FPV- 
NKp46- ILC IFN-g+ cell number
a
b NKp46- ILC IL-22+ cell number
c
d
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HIV-IL-4R antagonist vaccine group showed elevated IFN-γ expression by both 
NKp46+/- ILCs, whilst STAT6-/- mice vaccinated with unadjuvanted vaccine showed 
very low expression of IFN-γ (Fig. 5.7b & c). In contrast, compared to the FPV-HIV-
IL-13Rα2 adjuvanted vaccine group, the IL-13-/- mice given the unadjuvanted vaccine 
showed higher level of IFN-γ expression by both NKp46+/- ILC1/ILC3 (Fig. 5.7b & c). 
Moreover, expression of IL-22 by both NKp46+/- ILC1/ILC3s was significantly lower in 
FPV-HIV-IL-13Rα2 group compared to IL-13-/- mice given FPV-HIV vaccine (Fig. 
5.7d & e). Although there was no significant difference in NKp46- ILCI/ILC3-driven 
IL-22, significantly elevated IL-22 expression by NKp46+ ILC1/ILC3 were observed in 
FPV-HIV-IL-4R antagonist vaccinated group compared to STAT6-/- mice given FPV-
HIV (Fig. 5.7d & e). Interestingly, in each vaccine group tested the expression profile 
of NKp46+ ILCI/ILC3-driven IL-22 and IFN-γ were very similar, unlikeNKp46+- 
ILCI/ILC3, suggesting that NKp46+ and NKp46- subsets most likely are differentially 
regulated (Fig 5.7b & d).  
 
5.5 Discussion. 
This study revealed that ILC and their cytokine expression profile (IL-13, IFN-γ, and 
IL-22) at the vaccination site is vastly different in the scenario of transient sequestration 
verses permanent blockage of in IL-13, IL-4, and STAT6. Moreover, IL-17A was not 
detected in lung NKp46+/- ILC at any time points tested, unlike when IL-25 was 
transiently sequestered at vaccination site (Chapter 4). Data further supported the notion 
that the balance of ILC-2 driven IL-13 and ILC1/ILC3-driven IFN-γ play an important 
role in shaping downstream immune outcomes. Specifically, at 24 h post vaccination 
when IL-13 was permanently blocked (IL-13-/-), significantly elevated number of lung 
lineage- ST2/IL-33R+ ILC2s were detected at the vaccination, compared to transiently  
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inhibition of IL-13 in BALB/c mice (FPV-HIV-IL-13Rα2 adjuvanted vaccine) which 
showed the opposing effect. Interestingly, when STAT6-/- mice were given FPV-HIV, 
where IL-13 was unable to signal via the JAK/STAT6 pathway, and transient inhibition 
of STAT6 signalling in BALB/c mice (FPV-HIV-IL-4R antagonist adjuvanted vaccine) 
both showed elevated ST2/IL-33R+ ILC2s compared to WT control. These data clearly 
indicated that in the knockout scenario, different compensatory mechanism may be 
involved in modulating the ST2/IL-33R+ ILC2 at the vaccination site. For example, 
under STAT6 inhibitory condition, IL-13 may signal via the not well-defined IL-13Rα2 
pathway described by Hamid et al 2018 (Hamid et al EJI accepted). In this scenario, it 
is plausible that IL-13Rα2 may have the potential to complex with IL-13Rα1 to 
promote STAT3 signalling270. 
 
STAT6-/- mice given the FPV-HIV vaccine showed elevated ST2/IL-33R+ ILC2-driven 
IL-13 expression whilst reduced IFN-γ expression by both NKp46+/- ILC1/ILC3. 
However, when STAT6 signalling was transiently blocked in BALB/c mice using FPV-
HIV-IL-4R antagonist vaccination, the opposing effect was observed. Interestingly, IL-
13-/- mice given the FPV-HIV showed elevated expression of IFN-γ by NKp46+/- 
ILC1/ILC3, whereas BALB/c mice given the FPV-HIV-IL-13Rα2 adjuvanted vaccine 
showed low ST2/IL-33R+ ILC2-driven IL-13 expression and low NKp46+/- ILC1/ILC3-
driven IFN-γ. It is now established that IL-13 can modulate IFN-γ expression265, 266. 
These findings indicate that the balance between ST2/IL-33R+ ILC2-driven IL-13 and 
NKp46+/- ILC1/ILC3-driven IFN-γ at vaccination site is differentially modulated under 
IL-13 and STAT6 permanent verses transient inhibitory conditions.  
 
Our previous studies have demonstrated that the FPV-HIV-IL-4R/VV-HIV-IL-4R 
antagonist adjuvanted prime-boost vaccination can induce the HIV gag-specific IgG1 to 
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IgG2a antibody differentiation. unlike FPV-HIV-IL-13Rα/VV-HIV-13Rα adjuvanted 
vaccine strategy113. Similarly, IL-4-/-, STAT6-/- given FPV-HIV/VV-HIV was shown to 
induce elevated gag-specific IgG2a unlike IL-13-/- mice (Hamid et al EJI accepted), 
indicating that IL-13 signalling was detrimental for IgG1/IgG2a antibody differentiation 
(Fig.5.8a & b). When STAT6 signalling pathway was interrupted by FPV-HIV-IL-4R 
antagonist vaccine, elevated IFN-γ expression by both NKp46+/- ILC1/ILC3 were 
observed (Fig. 5.9a). It is now established that i) IFN-γ is required for antibody 
differentiation259, 260, 261, 262, 263, and IL-13 plays an important role in this process (Hamid 
et al EJI accepted), ii) IL-13Rα2 can act as an inhibitor of IL-4Rα chain and STAT6 
signalling119, and iii) also IL-4Rα and STAT6 signalling can inhibit IFN-γ expression 
by CD4+ T cells271. Moreover, IL-13 signalling via IL-13Rα2 pathway is involved in 
induction of TGF-β production272, 273, and TGF-β is known to be a key regulator for 
IgG2a antibody induction274, 275, 276. Thus, we postulate that in IL-4R antagonist 
inhibitor scenario, IL-13 may act on NKp46+/- ILC1/ILC3 to regulate IFN-γ expression. 
Specifically, via the IL-13Rα2 pathway and modulate IgG1/IgG2a antibody 
differentiation process. In STAT6-/- mice given the unadjuvanted vaccine scenario (Fig. 
5.9b), where low NKp46+/- ILC1/ILC3-driven IFN-γ expression and high ST2/IL-33R+ 
ILC2-driven IL-13 expression was observed, the IgG1/IgG2a antibody differentiation 
process is likely regulated by the balance of IL-13 and IFN-γ at the vaccination site, still 
via the IL-13Rα2 pathway.  
 
Interestingly, in IL-4-/- mice given the unadjuvanted vaccine (Fig. 5.10), lower ST2/IL-
33R+ ILC2-derived IL-13 expression was observed compared to STAT6-/- mice or WT 
BALB/c. This is not surprising as studies have shown that IL-4-/- lymphocytes express  
 
a
b
F
ig
. 5
.8
. I
L
-4
/I
L
-1
3 
si
gn
al
in
g 
fo
ll
ow
in
g 
B
A
L
B
/c
 m
ic
e 
gi
ve
n
 t
h
e 
F
P
V
-H
IV
-I
L
-1
3R

2 
ad
ju
va
n
te
d
 v
ac
ci
n
e 
(a
) 
an
d
 I
L
-
13
-/
-
m
ic
e 
gi
ve
n
 t
h
e 
co
n
tr
ol
 u
n
ad
ju
va
nt
ed
  v
ac
ci
n
e 
(F
P
V
-H
IV
) 
(b
).
?
?
a
b
F
ig
. 5
.9
. I
L
-4
/I
L
-1
3 
si
gn
al
in
g 
fo
ll
ow
in
g 
B
A
L
B
/c
 m
ic
e 
gi
ve
n
 t
h
e 
F
P
V
-H
IV
-I
L
-4
R
 a
n
ta
go
n
is
t 
va
cc
in
e 
(a
) 
an
d
 S
T
A
T
6-
/-
m
ic
e 
gi
ve
n
 t
h
e 
co
n
tr
ol
 u
n
ad
ju
va
n
te
d
  v
ac
ci
n
e 
(F
P
V
-H
IV
) 
(b
).
?
?
F
ig
. 5
.1
0.
 I
L
-4
/I
L
-1
3 
si
gn
al
in
g 
in
 I
L
-4
-/
-
m
ic
e 
fo
ll
ow
in
g
co
n
tr
ol
 u
n
ad
ju
va
nt
ed
  v
ac
ci
n
at
io
n
 (
F
P
V
-H
IV
).
?
173 
 
low IL-1377, 277, 278. Thus, knowing that IL-13Rα2 is the high affinity receptor for IL-13, 
we postulate that in IL-4-/- condition, IL-13 may act on NKp46+/- ILC1/ILC3 via the  
IL-13Rα2 to regulate IFN-γ expression and promote IgG1/IgG2a antibody 
differentiation. The lower IgG2a observed in IL-13-/- could be associated with 
redundancies in the knockout system, where compensatory mechanisms induce 
IgG1/IgG2a antibody differentiation, which is completely different to a transient 
inhibition of IL-13 (Fig 5.8a & b).  In contrast, in WT BALB/c mice this could be 
associated with IL-4Rα/STAT6 signalling pathway competing with IL-13Rα2, knowing 
that IL-4Rα prevents IL-13Rα2 interaction with type II complex279.  
 
Taking together the previous findings in our laboratory, current data indicated that if no 
ST2/IL-33R+ ILC2-derived IL-13 was detected at the vaccination site, no IgG2a 
antibody differentiation was observed regardless of the presence or absence of NKp46+/- 
ILC1/ILC3-derived IFN-γ (Table 5.1). These findings support the notion that i) ILC2-
derived IL-13 is a master regulator of the initial IgG1/IgG2a antibody differentiation 
process, likely associated with IL-13 signalling via STAT6 independent IL-13Rα2 
pathway and ii) co-regulation of ST2/IL-33R+ ILC2-derived IL-13 and NKp46+/- 
ILC1/ILC3-derived IFN-γ (specifically NKp46- ILC) play an important role in this 
process (Table 5.1). The mechanisms at the ILC level, involved in these processes 
warrant further investigation.  
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Chapter 6. 
Evaluation of IL-13Rα2, type I and II IL-4 receptor 
complexes on different ILC subsets following rFPV 
vaccination. 
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6.1 Abstract. 
This study demonstrated that the expression of IL-13Rα2, type I and II IL-4 receptor 
complexes on ST2/IL-33R+ ILC2 and NKp46- ILC1/ILC3 were co-regulated, 24 h post 
intranasal rFPV vaccination. Inhibition of STAT6 signalling significantly impacted the 
IL-13Rα2 expressions on both ST2/IL-33R+ ILC2 and NKp46- ILC1/ILC3, unlike IL-
13 inhibition, suggesting that under STAT6 inhibition conditions, IL-13 could signal via 
IL-13Rα2 pathway. As elevated number of ST2/IL-33R+ ILC2 expressing IL-13Rα2 
were detected in BALB/c mice given the FPV-HIV-IL-4R antagonist vaccine also 
indicated an autocrine regulation of IL-13 at the ILC2 via IL-13Rα2. The IL-4/IL-13 
receptor expression profile on NKp46+ ILC1/ILC3 and NKp46- ILC1/ILC3 were vastly 
different, suggesting that these cells may play different roles in downstream immune 
outcomes.  
 
6.2 Introduction. 
Data in previous chapters have demonstrated that ILC2-driven IL-13 can significantly 
modulate ILC1/ILC3 function (specifically, IFN-γ expression) and is a master regulator 
of the initial T and B cell activation in a STAT6 independent manner. However, the 
molecular mechanism by which ILC2-derived IL-13 regulating ILC1/ILC3 activity is 
not well understood. 
 
IL-4 and IL-13 signal via a complex receptor system92. The type I and type II IL-4 
receptor complexes consist of the γC/IL-4Rα and IL-4Rα/IL-13Rα1 respectively93 (Fig. 
1.10). IL-4 can signal via both type I and type II receptor complex by binding IL-4Rα94, 
95, signalling via the JAK/STAT6 pathway96, 97, 98. IL-13 can also bind to IL-13Rα1 
(type II IL-4 receptor complex) with low affinity (nM concentrations) and signal via the 
178 
 
JAK/STAT6 pathway93. Furthermore, under low IL-13 conditions (pM concentrations), 
it is also thought that IL-13 can signal via IL-13Rα2 pathway112 using a not yet 
characterised mechanism. Studies have shown that IL-13Rα2 can bind to IL-4Rα and 
inhibit IL-4/IL-13 signalling via the IL-13Rα1/IL-4Rα type II complex and 
JAK/STAT6 pathway117, 118, 119, 120. Also, in cancer studies IL-13Rα2 
activation/signalling has been associated with TGF-β production in the absence of 
functional IL-4Rα121. The dis-regulation of IL-13Rα2 in cancers280, 281, 282, 283 suggest 
that maintaining the optimal balance of IL-13 may be crucial for cell homeostasis and 
immune regulation.  
 
Given that i) IL-13Rα2 being the high affinity receptor for IL-13 compared to IL-
13Rα1, and ii) recent studies in the laboratory including Chapter 5 studies indicating 
that IL-13Rα2 could be involved in ILC2-driven IL-13 and ILC1/ILC3-driven IFN-γ 
regulation (specifically in the context of antibody differentiation), in this chapter, the 
possible mechanisms involved in this processes were assessed 24 h post vaccination. 
Specifically, by evaluating the IL-4/IL-13 receptors (IL-13Rα2, IL-13Rα1, IL-4Rα, and 
γC) on ILC subsets in i) WT BALB/c mice following FPV-HIV unadjuvanted or IL-4R 
antagonist and IL-13Rα2 adjuvanted vaccines, and ii) IL-13-/- and STAT6-/- mice 
following FPV-HIV unadjuvanted vaccination. (Note that in this study 24 h time point 
was chosen as Chapters 3-5 studies clearly demonstrated that ILC were mainly 
regulated at this timepoint). 
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6.3 Materials and Methods. 
6.3.1 Mice and immunisation. 
5-6 weeks old pathogen free female WT BALB/c, IL-13-/-, and STAT6-/- mice were 
obtained from the Australian Phenomics Facility, the Australian National University, 
and were maintained and handled under protocols indicated in 2.2.1. 1×107 PFU 
unadjuvanted FPV-HIV, FPV-HIV-IL-4R antagonist, or FPV-HIV-IL-13Rα2 
adjuvanted vaccines were administered to BALB/c mice (n = 4 per group) intranasally 
under mild isoflurane anaesthesia as per described in 2.2.5. IL-13-/- and STAT6-/- mice 
(n = 4 per group) were intranasally vaccinated with 1×107 PFU unadjuvanted FPV-HIV 
vaccine. Lungs were harvested in 2 ml of complete RPMI 24 h post vaccination, single 
cell lung suspensions were prepared, stained and analysed as per described in 2.2.6 and 
2.2.8.  
 
6.3.2 Surface staining. 
Surface staining was performed as per described in 2.2.8 using antibodies listed in 
Table 2.3. Specifically, 
ILC staining: APC/Cy7-conjugated anti-mouse CD45, and FITC-conjugated lineage 
cocktail were used to identify lineage- cells. PerCP/Cy5.5-conjugated anti-mouse 
ST2/IL-33R was used to identify the ILC2. Brilliant Violet 421-conjugated anti-mouse 
CD335 (NKp46) were used to identify ILC1/3 populations.  
 
IL-13Rα2, IL-13Rα1, IL-4Rα, and γC staining: PE-conjugated anti-mouse γC 
(CD132), PE-conjugated anti-mouse IL-4Rα (CD124), PE-conjugated anti-mouse IL-
13Rα1, and Biotin-conjugated anti-mouse IL-13Rα2 were used to evaluated type I (γC 
and IL-4Rα) and type II (IL-4Rα and IL-13Rα1) IL-4 receptor complex and IL-13Rα2 
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expression on different ILC subsets. PE-conjugated streptavidin was used as secondary 
antibody to detect the Biotin-conjugated IL-13Rα2 antibody. All receptors antibodies 
were stained separately to avoid spectral overlap as indicated in the Flowchart 6.1. 
Specifically, γC (PE), IL-4Rα (PE), IL-13Rα1 (PE) and IL-13Rα2 (Biotin) were 
stained with ILC master mix antibodies. Then γC, IL-4Rα, and IL-13Rα1 stained 
samples were directly fixed with 0.5% PFA as per described in 2.2.8. The IL-13Rα2 
stained samples were washed once with FACS buffer and then stained with PE-
conjugated Streptavidin for 15 min on ice in the dark, followed by washing and fixing 
with 0.5% PFA. All samples were analysed using a BD LSR Fortessa as per described 
in 2.2.8. All ILC subsets and their γC, IL-4Rα, IL-13Rα1, and IL-13Rα2 expression 
were analysed based on the FMO controls as per described in Fig. 6.1. 
 
Flowchart 6.1. ILC γC, IL-4Rα, IL-13Rα1, and IL-13Rα2 staining strategy. 
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6.4 Results. 
6.4.1 Elevated number of ST2/IL-33R+ ILC2 and NKp46- ILC1/ILC3 
were found to express IL-13Rα2 following FPV-HIV-IL-4R antagonist 
vaccination. 
To examine type I and type II IL-4 receptor complexes and IL-13Rα2 expression 
profiles on different ILC subsets, WT BALB/c mice were vaccinated intranasally with 
the unadjuvanted and adjuvanted vaccines and ILC subsets were evaluated using 
multicolour flow cytometry as per described in Materials and Methods. Data revealed 
that at 24 h post rFPV vaccination, IL-13Rα2, IL-13Rα1, IL-4Rα, and γC were 
expressed on both ST2/IL-33R+ ILC2 and NKp46+/- ILC1/ILC3 (Fig. 6.2a-d). 
 
When transient verses permanent inhibition of STAT6 (FPV-HIV-IL-4R antagonist vs 
STAT6-/-), elevated number of ST2/IL-33R+ ILC2 were found to express IL-13Rα2 
following IL-4R antagonist adjuvanted vaccination compared to BALB/c mice given 
the unadjuvanted FPV-HIV vaccination (p<0.05) (Fig. 6.3a). In contrast, no ST2/IL-
33R+ ILC2 obtained from STAT6-/- mice given the unadjuvanted vaccine were found to 
express IL-13Rα2 (Fig. 6.3a). However, no significant difference in ST2/IL-33R+ ILC2 
IL-13Rα1 expression was observed in any of the groups tested (Fig. 6.3b). Although no 
differences in γC and IL-4Rα expression were detected in BALB/c mice vaccinated 
with IL-4R antagonist adjuvanted and unadjuvanted vaccines, significantly lower 
number of ST2/IL-33R+ ILC2 from STAT6-/- mice given unadjuvanted FPV-HIV 
vaccine expressed these two receptors (Fig. 6.3c & d).  
 
When the densities of the different receptors on ILC subsets were accessed, no 
significant differences in IL-13Rα2 and IL-13Rα1 were detected on ST2/IL-33R+  
Fig. 6.2. Evaluation of type I (C chain and IL-4R) and type II
(IL-4R and IL-13R1) IL-4 receptor complexes and IL-13R2
expression on ILC following intranasal rFPV vaccination.
WT BALB/c mice (each group n = 4) were immunized intranasally
with unadjuvanted FPV-HIV vaccine. Using the flow cytometry gating
strategy indicated in materials and methods, ILC2s were defined as
CD45+ FSClow SSClow lineage- IL-33R/ST2+ cells, ILC1/ILC3 were
identified as CD45+ FSClow SSClow lineage- IL-33R/ST2- NKp46+/-
ILCs. The histogram FACS plots indicate the expression of IL-13R2
(a), IL-13R1 (b), IL-4R (c), and C chain (d) on different ILC
subsets in unimmunized WT BALB/c mice (black line) and 24 h post
intranasal unadjuvanted rFPV vaccinated WT BALB/c mice (blue
line) compared to isotype control.
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ILC2s (Fig. 6.4a & b). However, IL-4Rα densities on ST2/IL-33R+ ILC2 obtained 
from STAT6-/- mice given the unadjuvanted vaccine were significantly down-regulated 
compared to BALB/c mice given the adjuvanted or the unadjuvanted vaccines 
(p<0.0001 and p<0.001 respectively) (Fig. 6.4c). Similarly, down regulation of γC on 
ST2/IL-33R+ ILC2 was also observed in STAT6-/- mice compared to BALB/c given the 
unadjuvanted vaccine (Fig. 6.4d). 
 
Following rFPV vaccination, similar to ST2/IL-33R+ ILC2, elevated number of NKp46- 
ILC1/ILC3 were found to express IL-13Rα2 in FPV-HIV-IL-4R antagonist adjuvanted 
vaccine group compared to both BALB/c and STAT6-/-mice given unadjuvanted FPV-
HIV vaccination (p<0.01) (Fig. 6.5a). Interestingly, STAT6-/- mice given unadjuvanted 
FPV-HIV vaccine showed down-regulation of the IL-13Rα1 on NKp46- ILC1/ILC3 
compared to both BALB/c mice given unadjuvanted FPV-HIV or FPV-HIV-IL-4R 
antagonist adjuvanted vaccines (Fig. 6.5b). Moreover, transient inhibition of STAT6 
signalling (FPV-HIV-IL-4R antagonist) down-regulated the expression of IL-4Rα on 
NKp46- ILC1/ILC3s (Fig. 6.5c). Similarly, γC was also down-regulated on FPV-HIV-
IL-4R antagonist vaccinated NKp46- ILC1/ILC3s compared to unadjuvanted 
vaccination (p<0.05) (Fig. 6.5d). In the context of IL-4/IL-13 receptor densities, 
STAT6-/- mice given the unadjuvanted vaccine showed significant down-regulation of 
IL-13Rα2 on NKp46- ILC1/ILC3 compared to the other vaccine groups tested (Fig. 
6.6a). Interestingly, IL-13Rα1 or IL-4Rα was not modulated on NKp46- ILC1/ILC3 
(Fig. 6.6b & c), although STAT6 inhibition resulted in down-regulation of γC 
expression on these cells (Fig. 6.6d). 
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6.4.2 Following FPV-HIV-IL-13Rα2 adjuvanted vaccination, IL-13Ra2 
was not regulated on ST2/IL-33R+ ILC2 or NKp46- ILC1/ILC3. 
Next when IL-4/IL-13 receptor expression on ST2/IL-33R+ ILC2 were examined under 
transient verses permanent inhibition of IL-13 (FPV-HIV-IL-13Rα2 vs IL-13-/-), 
although expression of IL-13Rα2 on ST2/IL-33R+ ILC2 was not modulated, IL-13Rα1 
expression was significantly down regulated on IL-13-/- mice given the unadjuvanted 
vaccine (p<0.05) (Fig. 6.7a & b). Interestingly, in this scenario, elevated number of 
ST2/IL-33R+ ILC2 were found to express both γC and IL-4Rα following FPV-HIV-IL-
13Rα2 adjuvanted vaccination, unlike IL-13-/- mice given unadjuvanted FPV-HIV 
vaccine (p<0.001 and p<0.0001 respectively) (Fig. 6.7c & d). Furthermore, compare to 
the BALB/c mice given the unadjuvanted vaccine, mice that received FPV-HIV-IL-
13Rα2 adjuvanted vaccine showed significant regulation of type I IL-4 receptor 
complex on ST2/IL-33R+ ILC2 (Fig. 6.7c &d). In the context of IL-4/IL-13 receptor 
densities on ST2/IL-33R+ ILC2, the IL-13-/- mice given the unadjuvanted vaccine 
showed significantly lower IL-4Rα/γC expression (Fig. 6.8c & d). Interestingly, IL-
13Rα1 and IL-13Rα2 were not regulated in any of the groups tested (Fig. 6.8a & b).  
 
Under different IL-13 inhibition conditions, the IL-4/IL-13 receptor expression profiles 
were vastly different between ST2/IL-33R+ ILC2 and NKp46- ILC1/ILC3. Significantly 
elevated number of NKp46- ILC1/ILC3 were found to express IL-13Rα2 in the IL-13-/- 
mice given the unadjuvanted vaccine (Fig. 6.9a). However surprisingly, transient 
inhibition of IL-13 showed elevated number of NKp46- ILC1/ILC3 expressing IL-
13Rα1 compared to both BALB/c and IL-13-/- mice given the unadjuvanted vaccine 
(Fig. 6.9b). Elevated number of NKp46- ILC1/ILC3 were found to express IL-4Rα (Fig. 
6.9c), but not γC (Fig. 6.9d) obtained from IL-13-/- mice given unadjuvanted FPV-HIV  
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vaccine. In the transient verses permanent IL-13 inhibitory conditions, IL-13Rα2, IL-
4Rα, γC, but not IL-13Rα1 densities were differentially regulated on NKp46- 
ILC1/ILC3 (Fig. 6.10).  
 
6.4.3 Following transient or permanent inhibition of IL-4/IL-13, IL-
13Rα2 were not regulated on NKp46+ ILC1/ILC3 unlike NKp46- 
ILC1/ILC3. 
When IL-4/IL-13 receptors on NKp46+ ILC1/ILC3 were accessed under transient verses 
permanent inhibition vaccine conditions, surprisingly there were no significant 
differences in the number of NKp46+ ILC1/ILC3 expressing IL-13Rα2 in all vaccine 
groups tested (Fig. 6.11a). In contrast, the number of NKp46+ ILC1/ILC3 expressing γC, 
IL-4Rα, and IL-13Rα1 (Fig. 6.11b - c) were found to be significantly lower under 
permanent STAT6 or IL-13 inhibition (KO mice) compared to transient inhibition. 
Interestingly, both transient blockage of STAT6 (FPV-HIV-IL-4R antagonist) and IL-
13 (FPV-HIV-IL-13Rα2) showed significantly elevated number of NKp46+ ILC1/ILC3 
expressing γC, IL-4Rα, and IL-13Rα1 compared to BALB/c mice given the 
unadjuvanted FPV-HIV vaccine (Fig. 6.11b - c). Under permanent blockage of STAT6 
and IL-13 (KO mice), significant down-regulation of not only γC/IL-4Rα but also IL-
13Rα2 densities were detected on NKp46+ ILC1/ILC3 following vaccination, but not 
IL-13Rα1 (Fig. 6.12).  
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6.5 Discussion 
This study demonstrated that the expression of type I (γC/IL-4Rα) and type II (IL-
4Rα/IL-13Rα1) IL-4 receptor complexes and IL-13Rα2 on ILC subsets were 
differentially regulated 24 h post intranasal rFPV vaccination, specifically under 
permanent and transient inhibition of cytokine IL-13 and STAT6 signalling. Data 
revealed that although there was a correlation between the IL-4/IL-13 receptor 
regulation between ST2/IL-33R+ ILC2 and NKp46- ILC1/ILC3, the receptor regulation 
on NKp46+ ILC1/ILC3 were vastly different. Specifically, disruption of STAT6 
signalling significantly impacted the IL-13Rα2 expression on both ST2/IL-33R+ ILC2 
and NKp46- ILC1/ILC3, unlike IL-13 inhibition, indicating that STAT6 independent 
IL-13 signalling can activate IL-13Rα2 signalling. Hamid et al have recently reported 
the activation of this pathway under STAT6 inhibition in the context of B cell 
differentiation284. 
 
Specifically, FPV-HIV-IL-4R antagonist vaccination has shown to induce reduced 
expression of IL-13 by ST2/IL-33R+ ILC2 (Chapter 3). Interestingly, in this current 
study, elevated number of ST2/IL-33R+ ILC2 were found to express IL-13Rα2. The 
FPV-HIV-IL-4R antagonist vaccination has shown to induce IgG1 and IgG2a antibody 
differentiation most likely associated with IL-13 signalling via the not well-defined IL-
13Rα2 pathway284. Moreover, dendritic cells studies in our laboratory have further 
established that following viral vector-based vaccination (specifically rFPV), low IL-13 
in the milieu (pM conditions) can promote IL-13Rα2 signalling (Roy et al, Liu et al 
manuscript in preparation). Therefore, up-regulation of IL-13Rα2 on ST2/IL-33R+ 
ILC2 may suggest that under FPV-HIV-IL-4R antagonist vaccination condition (low 
IL-13), IL-13 may signal via IL-13Rα2 pathway. In contrast, in STAT6 KO mice given 
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the unadjuvanted vaccine elevated IL-13 expression by ST2/IL-33R+ ILC2 was detected 
(Chapter 5), and no expression of IL-13Rα2 was observed (Table 6.1). Roy, Liu et al 
have recently shown that IL-13Rα2 gets activated on DC under low (pM) IL-13 
concentrations, following viral vector vaccination (Roy, Liu et al in preparation).  
Collectively, these findings may explain the vastly different ILC2 IL-13Rα2 expression 
profiles observed under low (FPV-HIV-IL-4R antagonist adjuvanted vaccination) vs 
high (STAT6 KO FPV-HIV vaccination) IL-13 conditions. Findings may suggest an 
autocrine regulation of ILC2-derived-IL-13 via the IL-13Rα2 under certain conditions 
(FPV-HIV-IL-4R antagonist adjuvanted vaccination).  
 
In the context of FPV-HIV-IL-4R antagonist vaccination, elevated expression of IFN-γ 
by NKp46- ILC1/ILC3 was observed (Chapter 3). Interestingly, in this study, elevated 
expression of IL-13Rα2 was detected on these cells. In contrast, STAT6-/- mice given 
the unadjuvanted vaccination showed reduced IFN-γ expression by NKp46- ILC1/ILC3 
(Chapter 5) and reduce expression of IL-13Rα2 on these cells compared to FPV-HIV-
IL-4R antagonist vaccination. Recent studies in our laboratory have shown that ST2/IL-
33R+ ILC2 also express elevated IFN-γR (Jaeson et al in preparation). Taken together 
the i) ILC2-driven IL-13 and NKp46- ILC1/ILC3-driven IFN-γ expression profiles, and 
ii) the expression profile of IL-13Rα2 on ST2/IL-33R+ ILC2 and NKp46- ILC1/ILC3 
under STAT6 inhibitory conditions, plus iii) the ability of ILC2 to express elevated 
IFN-γR following vaccination (Jaeson et al in preparation), data support the notion that 
there is a co-regulation of ST2/IL-33R+ ILC2 and NKp46- ILC1/ILC3, and the balance 
of IL-13 and IFN-γ at the vaccination site plays an important role in this process.  
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Unlike IL-13, no IL-4 expression by ST2/IL-33R+ ILC2 was detected in any vaccine 
groups tested. Thus, the down-regulation of the type I receptor complex on STAT6-/- 
lung ST2/IL-33R+ ILC2 following the unadjuvanted vaccination compared to BLAB/c 
mice given the FPV-HIV-IL-4R antagonist or the unadjuvanted vaccines could be an 
inherent mechanism by which STAT6-/- mice regulate these receptors on ILC2 to 
regulate cytokine balance. Furthermore, reduced number of NKp46- ILC1/ILC3 were 
found to express both γC and IL-4Rα in FPV-HIV-IL-4R antagonist scenario. Knowing 
that IL-13Rα2 acts as an inhibitor of IL-4Rα119 and γC pairs with IL-4Rα to form type I 
complex93, the down-regulation of these two receptors on NKp46- ILC1/ILC3 could be 
associated with the elevated expression of IL-13Rα2 inhibiting type I (γC/IL-4Rα) 
complex formation, and IL-13 signalling via this pathway.  
 
The regulation of IL-4/IL-13 receptor expression on ILC were significantly different 
under STAT6 compared to IL-13 inhibition conditions.  Following FPV-HIV-IL-13Rα2 
adjuvanted and unadjuvanted vaccination, both IL-13Rα1 and IL-13Rα2 on ST2/IL-
33R+ ILC2 were not regulated, unlike the type I (γC/IL-4Rα) IL-4 receptor complex. 
No expression IL-13Rα2 and low expression of type I (γC/IL-4Rα) or type II (IL-
4Rα/IL-13Rα1) receptor complexes were detected on IL-13-/- ST2/IL-33R+ ILC2 
following unadjuvanted vaccination. In this scenario, although IL-4 expression by 
ST2/IL-33R+ ILC2 was not observed 24 h post vaccination, other cells in the milieu 
have high potential to express IL-4 to compensate for IL-13. Thus, the down-regulation 
of type I IL-4 receptor complex on IL-13-/- ILC2 could be an inherent mechanism by 
which ILC2 regulated IL-4 function. Furthermore, FPV-HIV-IL-13Rα2 induce low 
IFN-γ expression by NKp46- ILC1/ILC3 compared to BALB/c and IL-13-/- mice given 
unadjuvanted vaccine. (The hierarchy of this IFN-γ expression was, BALB/c 
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unadjuvanted > IL-13-/- unadjuvanted > BALB/c IL-13Rα2 adjuvanted (Table 6.1)). 
IFN-γ was significantly down-regulated and differentially regulated when IL-13 was 
sequestered from the vaccination site in WT BALB/c mice. The above findings further 
corroborate our notion that IL-13 is the master regulator of ILC2 and NKp46- 
ILC1/ILC3 activity/function. 
 
The IL-13Rα2, IL-13Rα1, IL-4Rα and γC receptor expression profiles on NKp46+ 
ILC1/ILC3 were found to be regulated in a vastly different manner compared to the 
other two ILC subsets. This suggested that this subset could have a different role in 
immune regulation following vaccination. Interestingly, no regulation of IL-13Rα2 on 
NKp46+ ILC1/ILC3 were detected under any of the IL-13 or STAT6 inhibitory 
conditions including BALB/C mice given the unadjuvanted vaccine. However 
interestingly, expression of γC, IL-4Rα, and IL-13Rα1 on NKp46+ ILC1/ILC3 were 
elevated following FPV-HIV-IL-4R antagonist and FPV-HIV-IL-13Rα2 adjuvanted 
vaccination scenarios unlike STAT6-/- or IL-13-/- mice given the unadjuvanted FPV-HIV 
vaccine. The expression of type I (γC/IL-4Rα) and type II (IL-4Rα/IL-13Rα2) IL-4 
receptor complexes on NKp46+ ILC1/ILC3 not IL-13Rα2, suggested that these cells 
most likely are not responsive to ILC2-driven IL-13. Furthermore, the low IFN-γ 
expression by these cells following vaccination, and no regulation of IL-13Rα2 on these 
cells, suggest that NKp46+ ILC1/ILC3 most likely may not be involved in the regulation 
of ILC2 balance during viral vector vaccination.  
 
Collectively, our findings indicated an autocrine regulation of IL-13 at the ILC2 level 
via IL-13Rα2 signalling, and co-regulation of ILC2-driven IL-13 and NKp46- 
ILC1/ILC3-driven by IFN-γR and IL-13Rα2 receptors respectively, 24 h post viral 
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vector vaccination. IL-13 is the master regulator of both ILC2 and NKp46- ILC1/ILC3 
(not NKp46+ ILC1/ILC3) responsible for shaping the downstream adaptive outcomes 
following viral vector vaccination. Specifically, this IFN-γR and IL-13Rα2 receptor 
regulation process at the ILC level may play an important role in regulation of B cell 
immunity. 
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Chapter 7. 
General discussion. 
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7.1 General discussion. 
This thesis for the first time demonstrated that 24 h following viral vector vaccination 
(rFPV) ILC activity were significantly modulated in a route dependent manner and 
ILC2-derived IL-13 at the vaccination site was a master regulator of the downstream T 
and B cell immune outcomes observed previously in the laboratory74, 75, 77, 113, 122, 123. By 
dissecting the cytokine expression profiles and regulation of IL-4/IL-13 receptor 
complexes on ILC under permanent (gene knockout) verses transient inhibition of IL-
13/IL-4, and STAT6, data revealed that ILC2-derived IL-13 at the vaccination site was 
most likely regulated by IL-13 signalling via the IL-13Rα2 pathway (under low IL-13 
conditions), following viral vector vaccination. At the ILC2 level there was an autocrine 
regulation of IL-13, and it also regulated ILC1/ILC3-driven IFN-γ via a STAT6 
independent mechanism, most likely IL-13Rα2 pathway (Chapter 5 & 6). Jaeson et al. 
have recently found elevated expression of IFN-γR on ILC2 24 h post viral vector 
vaccination (Jaeson et al in preparation). These findings proposed the exciting notion 
that the balance of ILC2-driven IL-13 and ILC1/ILC3-driven IFN-γ are co-regulated 
(Fig. 7.1) and this STAT6 independent regulation is associated with maintaining the 
balance of IL-13 and IFN-γ at the vaccinations site, shaping the downstream antibody 
immunity284.  
 
Intranasal verses intramuscular vaccination induced different ILC2 phenotypes (IL-
33R+ vs IL-25R+) associated with different NKp46+/- ILC1/ILC3 profiles, suggesting 
IL-13 and IFN-γ played different roles in ILC development in muscle and lung. 
Interestingly, the disruption of IL-25 at the lung mucosae, unlike IL-33 led to the 
generation of lineage- ST2/IL-33R- IL-25R+, lineage- ST2/IL-33R- TSLPR+ ILC2, and a 
unique lineage- ST2/IL-33R- IL-25R- TSLPR- ILC2 with vastly different IL-4/IL-13 
expression profiles, suggesting that IL-25 could be a key regulator of ILC2. Moreover,  
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sequestration of IL-25 also induced elevated expression of IL-17A and altered the IFN-γ 
expression by NKp46+/- ILC1/ILC3. Furthermore, knowing that i.m. IL-25BP 
vaccination also yielded vastly different outcomes, and i.m. IL-33BP vaccination also 
did not alter ILC development or activity (Ranasinghe et al in preparation) compared to 
intranasal vaccination, these findings clearly indicated that IL-25 regulated not only 
ILC2 but also ILC1/ILC3 differentiation, suggesting that IL-25 could be the master 
regulator of ILC development (at the precursor cell level). In contrast, IL-33 may play a 
role in ILC2 homing255 to the lung mucosae. Taken together the findings in this thesis, 
data support the notion that at the ILC level there is a hierarchy of cytokines IL-25 
compared to IL-13, where former regulates the fundamental development of all ILCs 
and the latter is involved in maintaining the balance of ILC2-driven IL-13 and 
ILC1/ILC3-driven IFN-γ and the resulting downstream immune outcomes. Knowing the 
high plasticity of ILC109, 163, 166, 208, 209, 210, 211 (Fig. 1.17), this is not entirely surprising as 
at the precursor level all ILC could be IL-25R+ and under different stimulation 
conditions, they could develop into different ILC phenotypes. Moreover, as TSLPR+ 
ILC2 were found to express IL-4 and IL-13 following i.n. FPV-HIV-IL-25BP 
vaccination, it would also be of interest to study the impact of inhibition or 
sequestration of TSLP at the vaccination site, and this warrants further investigation. 
 
 
Unlike chronic inflammatory conditions, viral vector vaccination induced uniquely 
different ILC subsets, indicating that ILCs are highly sensitive to different 
environmental conditions and they most likely are the gatekeepers of the immune 
system. Specifically, data revealed that under different infection conditions ILC-derived 
cytokines are differentially regulated most likely to prevent overdrive of the resulting 
immune outcomes, which was also substantiated by the data observed with permanent 
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vs transient inhibition of IL-13, IL-25 and STAT6 signalling. The various compensatory 
mechanisms in gene knockout animal models, highlight the caveats of using KO models 
in infection studies. Compensatory and/or redundancy mechanisms have been reported 
previously in the context of certain genetic diseases (gene mutations or deletions)285, 286, 
287.  Thus, in the context of understanding the functional differences of ILC following 
viral vector vaccination, studies using reporter mice would also be of more benefit288, 289, 
290. The current findings once again stress the importance of understanding the 
molecular mechanisms associated with i) route of vaccine delivery, ii) cytokine milieu 
and iii) vaccine vectors/adjuvants, when designing vaccines against chronic pathogens, 
as all these factors can significantly alter the ILC function/activity, resulting in vastly 
different adaptive immune outcomes.  
 
In conclusion, findings in this thesis demonstrated that different routes of vaccine 
delivery and different adjuvants can significantly modulate ILC function/activity at the 
vaccination site, as early as 24h post vaccination. ILC2-derived IL-13 and NKp46- 
ILC1/ILC3-derived IFN-γ balance, plays an important role in this process and is likely 
regulated via IL-13Ra2 in a STAT6 independent manner. Specifically, now knowing 
that the cytokine environment induced by ILC can significantly alter the DC recruitment 
and the downstream adaptive immune responses113, 122, 123 (Fig. 7.2), when designing 
vaccines against chronic pathogens, clear understanding of the ILC induced, could help 
design better vaccines in the future. Collectively, the data suggest that, ILC most likely 
are the gatekeepers of the immune system following viral vector vaccination, and the 
level of ILC2-derived IL-13 and NKp46- ILC1/ILC3-derived IFN-γ balance induced 
could be used as a predictor of the resulting downstream adaptive immune outcomes in 
the future.  
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7.2 Future directions. 
• Current data demonstrated that ILC subsets and their functions were 
significantly manipulated following different routes of rFPV vaccination (i.n. vs 
i.m.). Therefore, it would be of great interest to evaluate ILC function/activity i) 
following different routes of vaccine delivery, specifically intradermal, 
intrarectal and intravaginal vaccination and also ii) following different viral 
vector-based vaccination (for example recombinant MVA, VV Adenovirus 
vectors, including DNA-based vaccines). 
 
• This study for the first time demonstrated that ILC2 are the predominant source 
of IL-13 at the vaccination site and IL-13 is the master regulator of both ILC2 
and NKp46- ILC1/ILC3 responsible for shaping the downstream adaptive 
immune outcomes following viral vector vaccination. Also knowing that 
permanent vs transient inhibition of cytokines induced uniquely different 
immune outcomes, it would be of interest to transfer ILC2 from WT BALB/c 
mice into IL-13-/- mice (adaptive transfer studies), vaccinate mice with different 
routes and viral vectors and evaluate the innate and adaptive immune responses 
to further understand the role of IL-13 in ILC activity.  
 
• Also, using the different reporter mice systems associated with ILC may also 
help in gaining a better understanding of ILC activity. For example, IL-13 
reporter mice have been used intensively in ILC studies136, 291, 292, 293. Thus, it 
would be of interest to use BALB/c background IL-13 reporter mice during 
vaccination to track ILC2 activation. Moreover, Id2 and PLZF are two crucial 
genes involved in ILC development288, 289, 294, 295, 296, reporter mice of these two 
genes could also be used together with transcription factor fluorescence staining 
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to obtain better understanding of ILC development and activation process during 
IL-13Rα2, IL-4R antagonist and IL-25BP adjuvanted vs unadjuvanted 
vaccination. 
 
• To better understand the role of ILC development, following sequestration of 
IL-25 (IL-17E) compared to unadjuvanted vaccine conditions, evaluation of the 
IL-17/IL-25 receptor complexes may be of benefit. Furthermore, similar to 
recent studies in the laboratory (Jaeson et al in preparation), following IL-25BP 
and IL-33BP vaccination analyzing range of IL-17, IL-25 and also IL-13 related 
bio-markers (cytokines, receptors, transcription factors) on ILC at a single cell 
level using Fluidigm 48:48 arrays may help gain more knowledge of ILC 
development, specifically following viral vector vaccination.  
 
• Chapter 6 data suggested an autocrine regulation of IL-13 at the ILC2 level and 
ILC2-driven IL-13 regulating NKp46- ILC1/ILC3-driven IFN-γ via IL-13Rα2 
signalling. As we postulate a co-regulation of IL-13 and IFN-γ at the ILC level 
(Fig. 7.1), it would be of interest to assess i) the IFN-γR expression on ILC2 and 
NKp46- ILC1/ILC3 24 h post vaccination using FACS analysis and ii) also the 
role of NKp46+ ILC1/ILC3 during vaccination. 
 
• Moreover, data in this thesis have shown that IL-13Rα2 play an important role 
in the co-regulation of ILC2-driven IL-13 and ILC1/ILC3-driven IFN-γ. 
However, the exact mechanism by which this signalling occurs is still unclear. 
Therefore, evaluating the IL-13Rα2 signalling pathway and the possible 
downstream regulation would be of significant importance.  
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